melatonin has been researched along with Obesity in 167 studies
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " The tight connection between adipose tissue and the immune system has been demonstrated to play a crucial role in inflammation, and melatonin is important for circadian rhythm regulation and metabolic homeostasis, in which it orchestrates several molecular mechanisms involved in obesity and associated inflammation." | 9.22 | The role of melatonin in the molecular mechanisms underlying metaflammation and infections in obesity: A narrative review. ( Amatrudo, F; Colao, A; Graziadio, C; Liccardi, A; Montò, T; Muscogiuri, G; Negri, M; Patalano, R; Pivonello, C; Pivonello, R, 2022) |
| "This study aimed to carry out a broad narrative review of the metabolic profile and associations between melatonin, diabetes and obesity." | 9.12 | Melatonin and its Relationships with Diabetes and Obesity: A Literature Review. ( de Sá, LBPC; Filho, DR; Ramirez, AVG, 2021) |
| "The objective of this article is to review the basis supporting the usefulness of melatonin as an adjuvant therapy for breast cancer (BC) prevention in several groups of individuals at high risk for this disease." | 8.98 | Melatonin: A Molecule for Reducing Breast Cancer Risk. ( González-González, A; Mediavilla, MD; Sánchez-Barceló, EJ, 2018) |
| "Here, we review the known relations between hypertension and obesity to inflammation and postulate the endogenous protective effect of melatonin and its potential as a therapeutic agent." | 8.98 | Anti-Inflammatory Effects of Melatonin in Obesity and Hypertension. ( Diez, ER; Ferder, L; Manucha, W; Prado, NJ, 2018) |
| " Melatonin, liraglutide, and naltrexone/bupropion are examples of drugs with different mechanisms of action that have favorable effects on obesity or medication-related weight gain." | 8.91 | Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain. ( Howland, RH, 2015) |
| "To investigate, in the liver of adult offspring, the possible effects of melatonin supplementation in the obese mother during pregnancy and lactation." | 8.31 | Adult mice offspring of obese mothers supplemented with melatonin show lessened liver steatosis, inflammation, oxidative stress, and endoplasmic reticulum stress. ( Aguila, MB; Ajackson, M; Mandarim-de-Lacerda, CA; Marcondes-de-Castro, IA; Nagagata, BA, 2023) |
| " Our group has shown that melatonin totally or partially prevents the alterations that obesity causes in some neuroendocrine and inflammatory parameters indicative of oxidative stress." | 8.31 | Effect of Melatonin on Redox Enzymes Daily Gene Expression in Perirenal and Subcutaneous Adipose Tissue of a Diet Induced Obesity Model. ( Cano-Barquilla, P; Esquifino, AI; Fernández-Mateos, P; Jiménez-Ortega, V; Pérez-Miguelsanz, J; Virto, L, 2023) |
| " This study examined the effects of maternal obesity on human colostrum lymphocytes and the intracellular mechanisms of lymphocyte modulation in the presence of leptin, adiponectin, and melatonin via cell proliferation; the release of intracellular calcium; and apoptosis induction." | 8.31 | Leptin, Adiponectin, and Melatonin Modulate Colostrum Lymphocytes in Mothers with Obesity. ( Abreu, LC; Bezerra, IMP; Daboin, BEG; de Quental, OB; França, EL; Honório-França, AC; Morais, TC; Pereira, GDAV; Pessoa, RS, 2023) |
| "The aim of this study includes molecular pathway and network analysis by using a systems pharmacology approach to identify a potential therapeutic mechanism of melatonin on leptin resistance-induced obesity." | 8.12 | Therapeutic Target Analysis and Molecular Mechanism of Melatonin - Treated Leptin Resistance Induced Obesity: A Systematic Study of Network Pharmacology. ( Nachiappan, V; Suriagandhi, V, 2022) |
| "Melatonin attenuated weight gain, insulin resistance, adipocyte hypertrophy, inflammation, and hepatic steatosis induced by the HFD and increased energy expenditure." | 8.12 | Suppression of obesity by melatonin through increasing energy expenditure and accelerating lipolysis in mice fed a high-fat diet. ( Cai, S; Ding, C; Huang, Y; Jin, S; Li, D; Li, H; Shao, H; Wang, Y; Xu, L; Zhang, O; Zhu, Y, 2022) |
| "Melatonin limits obesity in rodents without affecting food intake and activity, suggesting a thermogenic effect." | 7.88 | Melatonin increases brown adipose tissue mass and function in Zücker diabetic fatty rats: implications for obesity control. ( Agil, A; Fernández Vázquez, G; Reiter, RJ, 2018) |
| "Melatonin deficiency has been associated with obesity and systemic inflammation." | 7.88 | Melatonin expression in periodontitis and obesity: An experimental in-vivo investigation. ( Cano, P; Esquifino, AI; Fernández-Mateos, P; González, J; Haugen, HJ; Jiménez-Ortega, V; Sanz, M; Virto, L, 2018) |
| "Melatonin has been shown to inhibit myocardial infarction-induced apoptosis, its function in heart failure with preserved ejection fraction (HFpEF) has not been investigated." | 7.88 | Melatonin improves cardiac function in a mouse model of heart failure with preserved ejection fraction. ( Dong, JZ; Gao, L; Guo, S; Li, L; Li, LN; Liang, C; Liu, Y; Liu, YZ; Tu, S; Wang, D; Yang, HB; Zhao, XY, 2018) |
| "Adjunctive melatonin therapy significantly reduced alveolar bone loss and exerted a protective anti-inflammatory effect mainly in those experimental animals affected by the co-morbidity of periodontitis and obesity." | 7.88 | Melatonin as adjunctive therapy in the treatment of periodontitis associated with obesity. ( Cano, P; Esquifino, AI; Fernández-Mateos, P; González, J; Haugen, HJ; Jiménez-Ortega, V; Sanz, M; Virto, L, 2018) |
| "The effects of melatonin, aluminum oxide, and polymethylsiloxane complex on the expression of LYVE-1 (lymphatic vessel endothelial hyaluronan receptor) in the liver were studied in db/db mice with experimental obesity and type 2 diabetes mellitus." | 7.83 | Effects of Melatonin, Aluminum Oxide, and Polymethylsiloxane Complex on the Expression of LYVE-1 in the Liver of Mice with Obesity and Type 2 Diabetes Mellitus. ( Arkhipov, SA; Ishchenko, IY; Klimontov, VV; Konenkov, VI; Michurina, SV; Rachkovskaya, LN; Zavyalov, EL, 2016) |
| "Resveratrol/melatonin combination effectively normalizes anthropometrical, biochemical, and histopathological parameters in ovariectomized rats with fructose diet-induced obesity and associated metabolic alterations." | 7.80 | Resveratrol- and melatonin-abated ovariectomy and fructose diet-induced obesity and metabolic alterations in female rats. ( Giri, PR; Majumdar, AS; Pai, SA, 2014) |
| "Chronic melatonin treatment has been shown to prevent the harmful effects of diet-induced obesity and reduce myocardial susceptibility to ischaemia-reperfusion injury (IRI)." | 7.80 | Short-term melatonin consumption protects the heart of obese rats independent of body weight change and visceral adiposity. ( Blackhurst, D; Huisamen, B; Lochner, A; Nduhirabandi, F; Strijdom, H, 2014) |
| "We studied the effects of melatonin on the status of immune organs and parameters of lipid metabolism in rats with alimentary obesity and parameters of lipid metabolism and immune status in Wistar rats kept on high-fat diet and receiving melatonin solution per os." | 7.80 | Effect of melatonin on cellular composition of the spleen and parameters of lipid metabolism in rats with alimentary obesity. ( Dushkin, MI; Khrapova, MV; Mel'nikova, EV; Michurina, SV; Panteleeva, NG; Shurlygina, AV; Tenditnik, MV; Trufakin, VA, 2014) |
| " Moreover, the aging process is also associated with obesity and reduction in melatonin synthesis from the pineal gland and other organs." | 7.79 | Melatonin improves insulin sensitivity independently of weight loss in old obese rats. ( Bacurau, RF; Bordin, S; Camporez, JP; Caperuto, LC; Carpinelli, AR; Carvalho, CR; Cipolla-Neto, J; do Amaral, FG; Hirata, E; Marçal, AC; Peliciari-Garcia, RA; Ribeiro, LM; Siqueira-Filho, MA; Zanuto, R, 2013) |
| "In this study, we hypothesized that melatonin administration can minimize alterations in aorta morphology in an animal model of obesity (ob/ob mice)." | 7.79 | Obesity-related dysfunction of the aorta and prevention by melatonin treatment in ob/ob mice. ( Castrezzati, S; Favero, G; Giugno, L; Lonati, C; Rezzani, R; Rodella, LF, 2013) |
| "The aim of this study was to determine the association of exposure to LAN in an uncontrolled home setting with melatonin secretion, obesity, dyslipidemia, and diabetes." | 7.79 | Exposure to light at night, nocturnal urinary melatonin excretion, and obesity/dyslipidemia in the elderly: a cross-sectional analysis of the HEIJO-KYO study. ( Ikada, Y; Iwamoto, J; Kurumatani, N; Nezu, S; Obayashi, K; Okamoto, N; Saeki, K; Tomioka, K, 2013) |
| "The study objective was to investigate the effects of melatonin on obesity and obesity-associated systolic hypertension and dyslipidemia in young male Zucker diabetic fatty (ZDF) rats, an experimental model of the metabolic syndrome." | 7.77 | Beneficial effects of melatonin on obesity and lipid profile in young Zucker diabetic fatty rats. ( Abuhamadah, S; Agil, A; El-Mir, MY; Navarro-Alarcón, M; Ruiz, R; Vázquez, GF, 2011) |
| "The atypical antipsychotic drug olanzapine increases body weight and visceral adiposity in schizophrenia." | 7.74 | Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. ( Burke, BL; Crites, NJ; Raskind, MA; Rasmussen, DD; Tapp, AM, 2007) |
| "The study in ovariectomized (Ovx) rats, as a model of menopausal status, of the effects of melatonin (M) and/or estradiol (E), associated or not with food restriction, on body weight (BW) and serum leptin levels." | 7.74 | Melatonin and estradiol effects on food intake, body weight, and leptin in ovariectomized rats. ( Alonso-Gonzalez, C; Cos, S; Gonzalez, A; Martinez-Campa, CM; Mediavilla, MD; Sanchez-Barcelo, EJ; Sanchez-Mateos, S, 2007) |
| " Because hypothalamic lesions may explain daytime sleepiness in craniopharyngioma patients, salivary melatonin and cortisol concentrations were examined in severely obese (BMI>or=4SD) and non severely obese (BMI<4SD) craniopharyngioma patients (n=79), patients with hypothalamic pilocytic astrocytoma (n=19), and control subjects (n=30)." | 7.73 | Melatonin treatment in obese patients with childhood craniopharyngioma and increased daytime sleepiness. ( Emser, A; Faldum, A; Gebhardt, U; Handwerker, G; Kolb, R; Müller, HL; Sörensen, N, 2006) |
| "Melatonin is involved in the regulation of seasonal obesity in various species, including some rodents." | 7.72 | Melatonin reduces body weight gain in Sprague Dawley rats with diet-induced obesity. ( Bros, A; Casteilla, L; Delagrange, P; Desbazeille, M; Louche, K; Pénicaud, L; Prunet-Marcassus, B; Renard, P, 2003) |
| " Because hypothalamic lesions may explain daytime sleepiness in craniopharyngioma patients, salivary melatonin and cortisol concentrations were examined in obese and nonobese craniopharyngioma patients (n = 79), patients with hypothalamic pilocytic astrocytoma (n = 19), and control subjects (n = 30)." | 7.71 | Melatonin secretion and increased daytime sleepiness in childhood craniopharyngioma patients. ( Faldum, A; Handwerker, G; Müller, HL; Sörensen, N; Wollny, B, 2002) |
| "To investigate whether the function of pinealocytes is altered in obesity, nocturnal melatonin (MT) secretion was determined in nine healthy subjects and compared with that of eight obese individuals." | 7.68 | Effect of short-term fasting on nocturnal melatonin secretion in obesity. ( Röjdmark, S; Rössner, S; Wetterberg, L, 1992) |
| "Patients with hypothyroidism were found to have higher peak serum melatonin values, total nocturnal melatonin secretion, and urinary excretion of melatonin than normal individuals (Peak melatonin values: 0." | 7.68 | Nocturnal melatonin secretion in thyroid disease and in obesity. ( Berg, A; Röjdmark, S; Rössner, S; Wetterberg, L, 1991) |
| "Two experiments examined the effects of photoperiod, melatonin, and diet on body weight in female Syrian hamsters (Mesocricetus auratus)." | 7.67 | Seasonal obesity in Syrian hamsters: effects of age, diet, photoperiod, and melatonin. ( Bartness, TJ; Wade, GN, 1984) |
| "Daily plasma melatonin profiles were determined by RIA in exogenously obese and Prader-Willi syndrome children." | 7.66 | The daily profile of plasma melatonin in obese and Prader-Willi syndrome children. ( Abastillas, P; Chen, HC; McNemar, A; Sidbury, JB; Tamarkin, L, 1982) |
| "Leptin is a primary appetite-regulating hormone that binds to its receptors in the hypothalamic cell membrane and regulates downstream appetite-regulating neurons NPY/AgRp and POMC in the hypothalamus." | 6.82 | Protective Effects of Melatonin against Obesity-Induced by Leptin Resistance. ( Nachiappan, V; Suriagandhi, V, 2022) |
| " Supplementation dosage studies and more thorough clinical trials are needed to ascertain not only the relevance of such findings but also the efficacy of melatonin supplementation." | 6.72 | Melatonin supplementation in the management of obesity and obesity-associated disorders: A review of physiological mechanisms and clinical applications. ( Bueno, AA; Cipolla-Neto, J; Genario, R; Santos, HO, 2021) |
| "Obesity is a predominant risk factor in ischemic stroke and is commonly comorbid with it." | 6.72 | Ischemic stroke, obesity, and the anti-inflammatory role of melatonin. ( Govitrapong, P; Tocharus, C; Tocharus, J; Yawoot, N, 2021) |
| "Melatonin is a multifunctional signaling hormone synthesized and secreted primarily by the pineal gland." | 6.66 | Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of Covid-19. ( El-Missiry, MA; El-Missiry, ZMA; Othman, AI, 2020) |
| "Melatonin is a pineal secretory product involved in numerous actions, such as regulation of internal biological clocks and energy metabolism, and it functions as an antioxidant and as an anti-inflammatory agent." | 6.52 | Inter-relationships of the chronobiotic, melatonin, with leptin and adiponectin: implications for obesity. ( Reiter, RJ; Szewczyk-Golec, K; Woźniak, A, 2015) |
| "Melatonin is an old and ubiquitous molecule in nature showing multiple mechanisms of action and functions in practically every living organism." | 6.50 | Melatonin, energy metabolism, and obesity: a review. ( Afeche, SC; Amaral, FG; Cipolla-Neto, J; Reiter, RJ; Tan, DX, 2014) |
| "Obesity is associated with an oxidative stress status, defined as an excessive production of reactive oxygen species (ROS) compared to the level of antioxidants acting in the natural defence systems." | 6.50 | Obesity and oxidative stress: potential roles of melatonin as antioxidant and metabolic regulator. ( Bonnefont-Rousselot, D, 2014) |
| "Obesity has become an epidemic in industrialized and developing countries." | 6.48 | Obesity and metabolic syndrome: association with chronodisruption, sleep deprivation, and melatonin suppression. ( Korkmaz, A; Ma, S; Reiter, RJ; Tan, DX, 2012) |
| "Melatonin has been shown to have beneficial effects in cardiovascular disorders including ischaemic heart disease and hypertension." | 6.48 | Melatonin and the metabolic syndrome: a tool for effective therapy in obesity-associated abnormalities? ( du Toit, EF; Lochner, A; Nduhirabandi, F, 2012) |
| "Melatonin is an effective chronobiotic agent changing the phase and amplitude of the sleep/wake rhythm and having cytoprotective and immunomodulatory properties useful to prevent a number of MS sequels." | 6.47 | Disrupted chronobiology of sleep and cytoprotection in obesity: possible therapeutic value of melatonin. ( Cardinali, DP; Pagano, ES; Reynoso, R; Scacchi Bernasconi, PA; Scacchi, P, 2011) |
| "Melatonin has been proven to have antiarrhythmic potential; however, several studies have recently challenged this view." | 5.91 | Melatonin increases susceptibility to atrial fibrillation in obesity via Akt signaling impairment in response to lipid overload. ( Fan, J; Fu, Y; Jiang, T; Liu, B; Liu, P; Qin, X; Zhang, Y; Zheng, Q, 2023) |
| "Obesity is well-established as a common comorbidity in ischemic stroke." | 5.91 | Melatonin modulates the aggravation of pyroptosis, necroptosis, and neuroinflammation following cerebral ischemia and reperfusion injury in obese rats. ( Govitrapong, P; Sengking, J; Tocharus, C; Tocharus, J; Yawoot, N, 2023) |
| "Melatonin is a sleep-related neurohormone and affected by the circadian rhythm and light/dark cycles." | 5.72 | Melatonin protects against body weight gain induced by sleep deprivation in mice. ( Hu, S; Liu, X; Wang, Y; Wei, S; Zhang, R, 2022) |
| "Leptin is an adipokine secreted in a manner dependent on the circadian rhythm that ultimately reduces food intake." | 5.48 | Melatonin Prevents the Harmful Effects of Obesity on the Brain, Including at the Behavioral Level. ( Bermejo-Millo, JC; Boga, JA; Caballero, B; Coto-Montes, A; de Luxán-Delgado, B; Pérez-Martínez, Z; Potes, Y; Rubio-González, A; Solano, JJ; Vega-Naredo, I, 2018) |
| "Excess weight and obesity are severe public health threats worldwide." | 5.46 | Melatonin prevents obesity through modulation of gut microbiota in mice. ( Hong, F; Jia, L; Jin, X; Wang, J; Wang, S; Xu, P; Xue, T; Zhai, Y, 2017) |
| "Obesity is a common risk factor for non-alcoholic fatty liver disease (NAFLD)." | 5.43 | Hepatic Macrosteatosis Is Partially Converted to Microsteatosis by Melatonin Supplementation in ob/ob Mice Non-Alcoholic Fatty Liver Disease. ( Aleksic, M; Favero, G; Golic, I; Korac, A; Lavazza, A; Rezzani, R; Rodella, LF; Stacchiotti, A, 2016) |
| "Melatonin treatment alone improved circadian activity rhythms, attenuated induction of β-cell failure, and enhanced glucose tolerance." | 5.43 | Administration of Melatonin and Metformin Prevents Deleterious Effects of Circadian Disruption and Obesity in Male Rats. ( Hoang, J; Matveyenko, AV; Nguyen, A; Rakshit, K; Thomas, AP; Vongbunyong, K, 2016) |
| "Melatonin can reduce damage to male rodents' gonadal tissue and improve sperm count, motility, and morphology in metabolic diseases." | 5.41 | Protective effects of melatonin against oxidative stress induced by metabolic disorders in the male reproductive system: a systematic review and meta-analysis of rodent models. ( Ala, M; Azarpira, N; Dehdari Ebrahimi, N; Ebrahimi, F; Pakbaz, S; Sadeghi, A, 2023) |
| " This study is aimed at determining the effects of melatonin supplementation on body weight, nody mass index (BMI), waist circumference (WC), and body fat mass percentage (BFMP) in people with overweight or obesity." | 5.41 | Melatonin Supplementation and Anthropometric Indices: A Randomized Double-Blind Controlled Clinical Trial. ( Amiri, Z; Djafarian, K; Ghaffarian-Bahraman, A; Hassanipour, S; Jahangir, F; Mohammadi, S; Mohsenpour, MA; Rastmanesh, R, 2021) |
| "Melatonin treatment reduced the BW gain, visceral adiposity, blood TRIG, serum insulin, homeostatic model assessment index and thiobarbituric acid reactive substances in the DIO group." | 5.37 | Chronic melatonin consumption prevents obesity-related metabolic abnormalities and protects the heart against myocardial ischemia and reperfusion injury in a prediabetic model of diet-induced obesity. ( Blackhurst, D; Du Toit, EF; Lochner, A; Marais, D; Nduhirabandi, F, 2011) |
| " The tight connection between adipose tissue and the immune system has been demonstrated to play a crucial role in inflammation, and melatonin is important for circadian rhythm regulation and metabolic homeostasis, in which it orchestrates several molecular mechanisms involved in obesity and associated inflammation." | 5.22 | The role of melatonin in the molecular mechanisms underlying metaflammation and infections in obesity: A narrative review. ( Amatrudo, F; Colao, A; Graziadio, C; Liccardi, A; Montò, T; Muscogiuri, G; Negri, M; Patalano, R; Pivonello, C; Pivonello, R, 2022) |
| "This study aimed to carry out a broad narrative review of the metabolic profile and associations between melatonin, diabetes and obesity." | 5.12 | Melatonin and its Relationships with Diabetes and Obesity: A Literature Review. ( de Sá, LBPC; Filho, DR; Ramirez, AVG, 2021) |
| "The purpose of this manuscript is to review the evidence generated by clinical trials of pharmaceuticals in autism spectrum disorder (ASD), describe challenges in the conduct of such trials, and discuss future directions RECENT FINDINGS: Clinical trials in ASD have produced several compounds to adequately support the pharmacological treatment of associated symptom domains: attention deficit hyperactivity disorder (methylphenidate, atomoxetine, and alpha agonists), irritability/aggression (risperidone and aripiprazole), sleep (melatonin), and weight gain associated with atypical antipsychotic use (metformin)." | 4.98 | Clinical trials in autism spectrum disorder: evidence, challenges and future directions. ( Anagnostou, E, 2018) |
| "The objective of this article is to review the basis supporting the usefulness of melatonin as an adjuvant therapy for breast cancer (BC) prevention in several groups of individuals at high risk for this disease." | 4.98 | Melatonin: A Molecule for Reducing Breast Cancer Risk. ( González-González, A; Mediavilla, MD; Sánchez-Barceló, EJ, 2018) |
| "Here, we review the known relations between hypertension and obesity to inflammation and postulate the endogenous protective effect of melatonin and its potential as a therapeutic agent." | 4.98 | Anti-Inflammatory Effects of Melatonin in Obesity and Hypertension. ( Diez, ER; Ferder, L; Manucha, W; Prado, NJ, 2018) |
| " There has also been a marked increase in the prevalence of metabolic syndrome in recent decades, which has been associated with a reduction in nocturnal pineal production of melatonin with aging and an increased risk of coronary diseases, type 2 diabetes mellitus (T2DM) and death." | 4.90 | Melatonin and metabolic regulation: a review. ( A-Serrano, MM; Acuña-Castroviejo, D; Agil, A; Blanca-Herrera, RM; Fernández-Vázquez, G; Navarro-Alarcón, M; Ruiz-Ojeda, FJ, 2014) |
| "High circulating concentrations of leptin in obesity are associated with an apparent loss of its characteristic anorexic action within the hypothalamic region of the brain." | 4.82 | Appetite regulation and seasonality: implications for obesity. ( Adam, CL; Mercer, JG, 2004) |
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| "Participants with overweight/obesity body fat percentages ate 50% of their daily calories significantly closer to model-predicted melatonin onset from light and activity data (0." | 4.31 | Later energy intake relative to mathematically modeled circadian time is associated with higher percentage body fat. ( Barger, LK; Brown, LS; Garaulet, M; Klerman, EB; McHill, AW; Phillips, AJK; Scheer, FAJL, 2023) |
| " The aim of this study was to investigate whether melatonin and histidine, alone or in combination, could produce weight loss, meanwhile improve the cognitive processes." | 4.31 | Nano-melatonin and-histidine modulate adipokines and neurotransmitters to improve cognition in HFD-fed rats: A formula to study. ( Abo-ElMatty, DM; Farid, O; Ghattas, MH; Hegazy, HA; Omar, NN; Saleh, S, 2023) |
| "To investigate, in the liver of adult offspring, the possible effects of melatonin supplementation in the obese mother during pregnancy and lactation." | 4.31 | Adult mice offspring of obese mothers supplemented with melatonin show lessened liver steatosis, inflammation, oxidative stress, and endoplasmic reticulum stress. ( Aguila, MB; Ajackson, M; Mandarim-de-Lacerda, CA; Marcondes-de-Castro, IA; Nagagata, BA, 2023) |
| " This study examined the effects of maternal obesity on human colostrum lymphocytes and the intracellular mechanisms of lymphocyte modulation in the presence of leptin, adiponectin, and melatonin via cell proliferation; the release of intracellular calcium; and apoptosis induction." | 4.31 | Leptin, Adiponectin, and Melatonin Modulate Colostrum Lymphocytes in Mothers with Obesity. ( Abreu, LC; Bezerra, IMP; Daboin, BEG; de Quental, OB; França, EL; Honório-França, AC; Morais, TC; Pereira, GDAV; Pessoa, RS, 2023) |
| "The preventative effect of melatonin on the development of obesity and the progression of fatty liver under a high-fat diet (HFD) has been well elucidated through previous studies." | 4.31 | Protective Effects of Melatonin in High-Fat Diet-Induced Hepatic Steatosis via Decreased Intestinal Lipid Absorption and Hepatic Cholesterol Synthesis. ( Choi, Y; Kim, AL; Kim, B; Kim, Y; Ku, H; Lee, G, 2023) |
| "Patients with obesity and menstrual dysfunction are more likely to suffer from various sleep disorders and have lower levels of melatonin in saliva and 6-sulfatoxymelatonin in urine." | 4.12 | [Melatonin status in obese patients with ovarian dysfunction at reproductive age]. ( Absatarova, YS; Andreeva, EN; Grigoryan, OR; Mikheev, RK; Sheremetyeva, EV, 2022) |
| "Melatonin has shown beneficial effects on obesity, both in humans and experimental models, via regulating the altered circadian rhythm and thus ameliorating the gut dysbiosis associated with this metabolic condition." | 4.12 | The melatonergic agonist agomelatine ameliorates high fat diet-induced obesity in mice through the modulation of the gut microbiome. ( Algieri, F; Diez-Echave, P; Duarte, J; Gálvez, J; García, F; Garrido-Mesa, J; Hidalgo-García, L; Morón, R; Rodríguez-Cabezas, ME; Rodríguez-Nogales, A; Romero, M; Ruiz-Malagón, AJ; Sánchez, M; Toral, M; Vezza, T, 2022) |
| "Melatonin attenuated weight gain, insulin resistance, adipocyte hypertrophy, inflammation, and hepatic steatosis induced by the HFD and increased energy expenditure." | 4.12 | Suppression of obesity by melatonin through increasing energy expenditure and accelerating lipolysis in mice fed a high-fat diet. ( Cai, S; Ding, C; Huang, Y; Jin, S; Li, D; Li, H; Shao, H; Wang, Y; Xu, L; Zhang, O; Zhu, Y, 2022) |
| " In addition, the present results suggest that melatonin supplementation attenuates adipose-hepatic metabolic dysfunction, accompanying obesity by suppression of oxidative stress/inflammation-dependent mechanism and increasing circulating obestatin." | 4.02 | Protective role of melatonin against adipose-hepatic metabolic comorbidities in experimentally induced obese rat model. ( Akintayo, CO; Atuma, CL; Aturamu, A; Badejogbin, OC; Mahmud, H; Obayemi, MJ; Olaniyi, KS; Oniyide, AA; Saidi, AO, 2021) |
| "Chronodisruption leads to obesity and other metabolic disorders that can be alleviated by food-derived potential chronobiotics, such as phytomelatonin (PMT), phenolic compounds (PCs) and dietary fiber rich pistachios." | 4.02 | In vitro gastrointestinal digestion and simulated colonic fermentation of pistachio nuts determine the bioaccessibility and biosynthesis of chronobiotics. ( Campos-Vega, R; Dufoo-Hurtado, E; Loarca-Piña, G; Olvera-Bautista, R; Wall-Medrano, A, 2021) |
| "The results suggest that melatonin is a possible mechanism for maternal-infant protection against obesity and restores the functional activity of colostrum phagocytes in obese mothers." | 3.91 | Melatonin Action on the Activity of Phagocytes from the Colostrum of Obese Women. ( de Abreu, LC; de Quental, OB; França, EL; Fujimori, M; Honorio-França, AC; Morais, TC; Pessoa, RS, 2019) |
| "Melatonin deficiency has been associated with obesity and systemic inflammation." | 3.88 | Melatonin expression in periodontitis and obesity: An experimental in-vivo investigation. ( Cano, P; Esquifino, AI; Fernández-Mateos, P; González, J; Haugen, HJ; Jiménez-Ortega, V; Sanz, M; Virto, L, 2018) |
| "It seems that adequate melatonin treatment exerts anti-obesity protective effects, also in a diet-induced obesity zebrafish model, that might be the result of the restoration of many factors: the final endpoint reached is weight loss and stabilization of weight gain." | 3.88 | Melatonin treatment suppresses appetite genes and improves adipose tissue plasticity in diet-induced obese zebrafish. ( Abbate, F; Germanà, A; Guerrera, MC; Laura, R; Levanti, M; Mania, M; Montalbano, G; Navarra, M; Vega, JA, 2018) |
| "Melatonin has been shown to inhibit myocardial infarction-induced apoptosis, its function in heart failure with preserved ejection fraction (HFpEF) has not been investigated." | 3.88 | Melatonin improves cardiac function in a mouse model of heart failure with preserved ejection fraction. ( Dong, JZ; Gao, L; Guo, S; Li, L; Li, LN; Liang, C; Liu, Y; Liu, YZ; Tu, S; Wang, D; Yang, HB; Zhao, XY, 2018) |
| "Adjunctive melatonin therapy significantly reduced alveolar bone loss and exerted a protective anti-inflammatory effect mainly in those experimental animals affected by the co-morbidity of periodontitis and obesity." | 3.88 | Melatonin as adjunctive therapy in the treatment of periodontitis associated with obesity. ( Cano, P; Esquifino, AI; Fernández-Mateos, P; González, J; Haugen, HJ; Jiménez-Ortega, V; Sanz, M; Virto, L, 2018) |
| "The main aim of this study was to research new treatments following peripheral nerve injury involving melatonin (Mel), acetyl-l-carnitine (ALCAR), and leptin (Lep) using updated unbiased methods at the stereological and electron microscopic levels." | 3.85 | Possible effects of some agents on the injured nerve in obese rats: A stereological and electron microscopic study. ( Altun, G; Altunkaynak, BZ; Geuna, S; Kaplan, S; Muratori, L; Onger, ME; Türkmen, AP, 2017) |
| " The altered proteins are related to the development of liver pathology, such as cirrhosis (α1-antiproteinase), thrombosis (fibrinogen, plasminogen), and inflammation (mannose-binding protein A, complement C4, complement factor B), contributing to liver steatosis or hepatic cell death." | 3.85 | High-fat diet-induced plasma protein and liver changes in obese rats can be attenuated by melatonin supplementation. ( Govitrapong, P; Isarankura-Na-Ayudhya, C; Kitidee, K; Klosen, P; Pannengpetch, S; Wongchitrat, P, 2017) |
| "For the last decade melatonin has attracted attention as a neuroregulator in pathogenesis of obesity and metabolic syndrome." | 3.85 | [METABOLIC SECRETION IN REPRODUCTIVE AGE WOMEN WITH OBESITY]. ( Asatiani, K; Chkheidze, N; Malazonia, A; Vekua, N; Zerekidze, T, 2017) |
| "The effects of melatonin, aluminum oxide, and polymethylsiloxane complex on the expression of LYVE-1 (lymphatic vessel endothelial hyaluronan receptor) in the liver were studied in db/db mice with experimental obesity and type 2 diabetes mellitus." | 3.83 | Effects of Melatonin, Aluminum Oxide, and Polymethylsiloxane Complex on the Expression of LYVE-1 in the Liver of Mice with Obesity and Type 2 Diabetes Mellitus. ( Arkhipov, SA; Ishchenko, IY; Klimontov, VV; Konenkov, VI; Michurina, SV; Rachkovskaya, LN; Zavyalov, EL, 2016) |
| "Resveratrol/melatonin combination effectively normalizes anthropometrical, biochemical, and histopathological parameters in ovariectomized rats with fructose diet-induced obesity and associated metabolic alterations." | 3.80 | Resveratrol- and melatonin-abated ovariectomy and fructose diet-induced obesity and metabolic alterations in female rats. ( Giri, PR; Majumdar, AS; Pai, SA, 2014) |
| "Melatonin seems to exert a protective effect on arteries from both ob/ob and CLM, counteracting the adverse effect of hypoxia and iberiotoxin." | 3.80 | Anticontractile activity of perivascular fat in obese mice and the effect of long-term treatment with melatonin. ( Agabiti-Rosei, C; Agabiti-Rosei, E; De Ciuceis, C; Favero, G; Heagerty, AM; Porteri, E; Rezzani, R; Rizzoni, D; Rodella, LF; Rossini, C; Withers, SB, 2014) |
| "Chronic melatonin treatment has been shown to prevent the harmful effects of diet-induced obesity and reduce myocardial susceptibility to ischaemia-reperfusion injury (IRI)." | 3.80 | Short-term melatonin consumption protects the heart of obese rats independent of body weight change and visceral adiposity. ( Blackhurst, D; Huisamen, B; Lochner, A; Nduhirabandi, F; Strijdom, H, 2014) |
| " Moreover, the aging process is also associated with obesity and reduction in melatonin synthesis from the pineal gland and other organs." | 3.79 | Melatonin improves insulin sensitivity independently of weight loss in old obese rats. ( Bacurau, RF; Bordin, S; Camporez, JP; Caperuto, LC; Carpinelli, AR; Carvalho, CR; Cipolla-Neto, J; do Amaral, FG; Hirata, E; Marçal, AC; Peliciari-Garcia, RA; Ribeiro, LM; Siqueira-Filho, MA; Zanuto, R, 2013) |
| "The aim of this study was to determine the association of exposure to LAN in an uncontrolled home setting with melatonin secretion, obesity, dyslipidemia, and diabetes." | 3.79 | Exposure to light at night, nocturnal urinary melatonin excretion, and obesity/dyslipidemia in the elderly: a cross-sectional analysis of the HEIJO-KYO study. ( Ikada, Y; Iwamoto, J; Kurumatani, N; Nezu, S; Obayashi, K; Okamoto, N; Saeki, K; Tomioka, K, 2013) |
| "The study objective was to investigate the effects of melatonin on obesity and obesity-associated systolic hypertension and dyslipidemia in young male Zucker diabetic fatty (ZDF) rats, an experimental model of the metabolic syndrome." | 3.77 | Beneficial effects of melatonin on obesity and lipid profile in young Zucker diabetic fatty rats. ( Abuhamadah, S; Agil, A; El-Mir, MY; Navarro-Alarcón, M; Ruiz, R; Vázquez, GF, 2011) |
| "Melatonin effect on body weight progression, mean levels and 24-hr pattern of circulating adiponectin, leptin, insulin, glucose, triglycerides and cholesterol were examined in rats fed a normal or a high-fat diet." | 3.76 | Melatonin effect on plasma adiponectin, leptin, insulin, glucose, triglycerides and cholesterol in normal and high fat-fed rats. ( Cano, P; Cardinali, DP; Esquifino, AI; Fernández-Mateos, MP; Jiménez-Ortega, V; Ríos-Lugo, MJ; Scacchi, PA, 2010) |
| "The atypical antipsychotic drug olanzapine increases body weight and visceral adiposity in schizophrenia." | 3.74 | Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. ( Burke, BL; Crites, NJ; Raskind, MA; Rasmussen, DD; Tapp, AM, 2007) |
| "The study in ovariectomized (Ovx) rats, as a model of menopausal status, of the effects of melatonin (M) and/or estradiol (E), associated or not with food restriction, on body weight (BW) and serum leptin levels." | 3.74 | Melatonin and estradiol effects on food intake, body weight, and leptin in ovariectomized rats. ( Alonso-Gonzalez, C; Cos, S; Gonzalez, A; Martinez-Campa, CM; Mediavilla, MD; Sanchez-Barcelo, EJ; Sanchez-Mateos, S, 2007) |
| " Because hypothalamic lesions may explain daytime sleepiness in craniopharyngioma patients, salivary melatonin and cortisol concentrations were examined in severely obese (BMI>or=4SD) and non severely obese (BMI<4SD) craniopharyngioma patients (n=79), patients with hypothalamic pilocytic astrocytoma (n=19), and control subjects (n=30)." | 3.73 | Melatonin treatment in obese patients with childhood craniopharyngioma and increased daytime sleepiness. ( Emser, A; Faldum, A; Gebhardt, U; Handwerker, G; Kolb, R; Müller, HL; Sörensen, N, 2006) |
| "Melatonin is involved in the regulation of seasonal obesity in various species, including some rodents." | 3.72 | Melatonin reduces body weight gain in Sprague Dawley rats with diet-induced obesity. ( Bros, A; Casteilla, L; Delagrange, P; Desbazeille, M; Louche, K; Pénicaud, L; Prunet-Marcassus, B; Renard, P, 2003) |
| " Because hypothalamic lesions may explain daytime sleepiness in craniopharyngioma patients, salivary melatonin and cortisol concentrations were examined in obese and nonobese craniopharyngioma patients (n = 79), patients with hypothalamic pilocytic astrocytoma (n = 19), and control subjects (n = 30)." | 3.71 | Melatonin secretion and increased daytime sleepiness in childhood craniopharyngioma patients. ( Faldum, A; Handwerker, G; Müller, HL; Sörensen, N; Wollny, B, 2002) |
| "Melatonin levels in patients with hyperprolactinemia and hyperandrogenemia with normal body mass index are significantly higher compared to matched controls." | 3.70 | Endocrinological disorders. Focusing on melatonin's interactions. ( Blaicher, W; Gruber, DM; Huber, JC; Imhof, MH; Sator, MO; Schneeberger, C, 1999) |
| " We measured the circadian rhythms of plasma melatonin, serum cortisol, growth hormone (GH) and prolactin (PRL) in 26 patients with anorexia nervosa (AN), 27 with primary obesity (OB) and 7 with bulimia nervosa (BN)." | 3.69 | Circadian neuroendocrine functions in disorders of eating behavior. ( Ferrari, E; Fioravanti, M; Magri, F; Pontiggia, B; Rondanelli, M; Severgnini, S; Solerte, SB, 1997) |
| "These results demonstrate that the duration of melatonin-receptor exposure per day determines the onset of seasonal obesity in garden dormice and, on the other hand, that restriction of melatonin-receptor exposure by pharmacological treatment prevents it." | 3.69 | Effects of both a melatonin agonist and antagonist on seasonal changes in body mass and energy intake in the garden dormouse. ( Ambid, L; Atgié, C; Casteilla, L; Delagrange, P; Guardiola-Lemaitre, B; Hanoun, N; Le Gouic, S; Lesieur, D; Nibbelink, M; Renard, P, 1996) |
| "To investigate whether the function of pinealocytes is altered in obesity, nocturnal melatonin (MT) secretion was determined in nine healthy subjects and compared with that of eight obese individuals." | 3.68 | Effect of short-term fasting on nocturnal melatonin secretion in obesity. ( Röjdmark, S; Rössner, S; Wetterberg, L, 1992) |
| "Patients with hypothyroidism were found to have higher peak serum melatonin values, total nocturnal melatonin secretion, and urinary excretion of melatonin than normal individuals (Peak melatonin values: 0." | 3.68 | Nocturnal melatonin secretion in thyroid disease and in obesity. ( Berg, A; Röjdmark, S; Rössner, S; Wetterberg, L, 1991) |
| "The circadian rhythm of several plasma hormones (prolactin, growth hormone, adrenocorticotropic hormone (ACTH), cortisol, and melatonin) was simultaneously evaluated in 23 women with anorexia nervosa (AN), in 27 obese (OB) women, and in gender and age-matched healthy controls." | 3.68 | Hormonal circadian rhythms in eating disorders. ( Brambilla, F; Ferrari, E; Fraschini, F, 1990) |
| "Two experiments examined the effects of photoperiod, melatonin, and diet on body weight in female Syrian hamsters (Mesocricetus auratus)." | 3.67 | Seasonal obesity in Syrian hamsters: effects of age, diet, photoperiod, and melatonin. ( Bartness, TJ; Wade, GN, 1984) |
| "In order to study the possible relationships between melatonin secretion and pituitary-gonadal function, the circadian rhythm of plasma melatonin, the basal levels of estradiol-17beta and testosterone and the luteinizing hormone (LH) and follicle-stimulating hormone (FSH) response to luteinizing hormone-releasing hormone (LH-RH) stimulation were evaluated in normally cycling healthy women and in two groups of women with menstrual dysfunctions related to eating disorders (19 patients with anorexia nervosa and 16 with primary obesity)." | 3.67 | Melatonin and pituitary-gonadal function in disorders of eating behavior. ( Bossolo, PA; Brambilla, F; Comis, S; Esposti, G; Ferrari, E; Foppa, S; Fraschini, F; Licini, V, 1989) |
| "Daily plasma melatonin profiles were determined by RIA in exogenously obese and Prader-Willi syndrome children." | 3.66 | The daily profile of plasma melatonin in obese and Prader-Willi syndrome children. ( Abastillas, P; Chen, HC; McNemar, A; Sidbury, JB; Tamarkin, L, 1982) |
| "Pretreatment with melatonin (10 mg/kg) effectively reduced cardiac I/R injury by reducing infarct size, arrhythmia, and LV dysfunction." | 3.11 | Therapeutic potential of a single-dose melatonin in the attenuation of cardiac ischemia/reperfusion injury in prediabetic obese rats. ( Apaijai, N; Arunsak, B; Chattipakorn, N; Chattipakorn, SC; Chunchai, T; Maneechote, C; Singhanat, K; Sumneang, N, 2022) |
| " Supplementation dosage studies and more thorough clinical trials are needed to ascertain not only the relevance of such findings but also the efficacy of melatonin supplementation." | 2.72 | Melatonin supplementation in the management of obesity and obesity-associated disorders: A review of physiological mechanisms and clinical applications. ( Bueno, AA; Cipolla-Neto, J; Genario, R; Santos, HO, 2021) |
| "Obesity is a predominant risk factor in ischemic stroke and is commonly comorbid with it." | 2.72 | Ischemic stroke, obesity, and the anti-inflammatory role of melatonin. ( Govitrapong, P; Tocharus, C; Tocharus, J; Yawoot, N, 2021) |
| "Obesity is a common and complex health problem worldwide and can induce the development of Type 2 diabetes." | 2.66 | The roles of melatonin on kidney injury in obese and diabetic conditions. ( Lungkaphin, A; Promsan, S, 2020) |
| "Melatonin is a multifunctional signaling hormone synthesized and secreted primarily by the pineal gland." | 2.66 | Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of Covid-19. ( El-Missiry, MA; El-Missiry, ZMA; Othman, AI, 2020) |
| "Melatonin is a neurohormone, which plays multiple roles in regulating inflammation, blood pressure, insulin actions, and energy metabolism." | 2.66 | Elucidating the Regulatory Role of Melatonin in Brown, White, and Beige Adipocytes. ( Liu, J; Shan, T; Wang, Y; Xu, Z; You, W, 2020) |
| "Obstructive sleep apnea is the most prevalent type of obesity-related sleep disorder that lead to an increased risk for numerous chronic health conditions." | 2.61 | Obesity and sleep disturbance: the chicken or the egg? ( Annunziata, G; Barrea, L; Colao, A; Di Somma, C; Laudisio, D; Muscogiuri, G; Savastano, S, 2019) |
| "Obesity is associated with an oxidative stress status, defined as an excessive production of reactive oxygen species (ROS) compared to the level of antioxidants acting in the natural defence systems." | 2.50 | Obesity and oxidative stress: potential roles of melatonin as antioxidant and metabolic regulator. ( Bonnefont-Rousselot, D, 2014) |
| "Obesity has become an epidemic in industrialized and developing countries." | 2.48 | Obesity and metabolic syndrome: association with chronodisruption, sleep deprivation, and melatonin suppression. ( Korkmaz, A; Ma, S; Reiter, RJ; Tan, DX, 2012) |
| "Melatonin has been shown to have beneficial effects in cardiovascular disorders including ischaemic heart disease and hypertension." | 2.48 | Melatonin and the metabolic syndrome: a tool for effective therapy in obesity-associated abnormalities? ( du Toit, EF; Lochner, A; Nduhirabandi, F, 2012) |
| "The consequences of chronic sleep deprivation on energy expenditure have not been fully explored." | 2.47 | Chronic sleep deprivation and seasonality: implications for the obesity epidemic. ( Cizza, G; de Jonge, L; Galli, G; Requena, M, 2011) |
| "Melatonin is an effective chronobiotic agent changing the phase and amplitude of the sleep/wake rhythm and having cytoprotective and immunomodulatory properties useful to prevent a number of MS sequels." | 2.47 | Disrupted chronobiology of sleep and cytoprotection in obesity: possible therapeutic value of melatonin. ( Cardinali, DP; Pagano, ES; Reynoso, R; Scacchi Bernasconi, PA; Scacchi, P, 2011) |
| "Of particular relevance to breast cancer risk, melatonin may also block the estrogen receptor ERalpha and impact the enzyme aromatase, which produces estradiol." | 2.45 | Circulating melatonin and the risk of breast and endometrial cancer in women. ( Schernhammer, ES; Viswanathan, AN, 2009) |
| "Despite current treatments for polycystic ovary syndrome (PCOS), a considerable number of women with this syndrome do not reach the treatment goal, suggesting the presence of other probable misdiagnosed features of this syndrome that are not taken into account in the assessment and therefore in the therapeutical approach." | 1.91 | Evening chronotype is associated with hormonal and metabolic disorders in polycystic ovary syndrome. ( Barrea, L; Colao, A; de Alteriis, G; Docimo, A; Muscogiuri, G; Savastano, S; Verde, L; Vetrani, C, 2023) |
| "Melatonin has been proven to have antiarrhythmic potential; however, several studies have recently challenged this view." | 1.91 | Melatonin increases susceptibility to atrial fibrillation in obesity via Akt signaling impairment in response to lipid overload. ( Fan, J; Fu, Y; Jiang, T; Liu, B; Liu, P; Qin, X; Zhang, Y; Zheng, Q, 2023) |
| "Obesity is well-established as a common comorbidity in ischemic stroke." | 1.91 | Melatonin modulates the aggravation of pyroptosis, necroptosis, and neuroinflammation following cerebral ischemia and reperfusion injury in obese rats. ( Govitrapong, P; Sengking, J; Tocharus, C; Tocharus, J; Yawoot, N, 2023) |
| "Melatonin (Mel) is a hormone secreted by the pineal gland that regulates the circadian rhythms and improves obesity." | 1.91 | Effects of Melatonin Supplementation on Lipid Metabolism and Body Fat Accumulation in Ovariectomized Rats. ( Chien, YW; Hsu, LW, 2023) |
| "Overweight and obesity are associated with an increased risk of developing dementia and cognitive deficits." | 1.72 | Melatonin treatment improves cognitive deficits by altering inflammatory and neurotrophic factors in the hippocampus of obese mice. ( Abedi, A; Amani, M; Mansouri, S; Mohammadi, P; Salari, AA, 2022) |
| "Melatonin is a sleep-related neurohormone and affected by the circadian rhythm and light/dark cycles." | 1.72 | Melatonin protects against body weight gain induced by sleep deprivation in mice. ( Hu, S; Liu, X; Wang, Y; Wei, S; Zhang, R, 2022) |
| "Melatonin is an antioxidant that displays vasoprotective action in cardiovascular disease." | 1.62 | Melatonin reverses the loss of the anticontractile effect of perivascular adipose tissue in obese rats. ( Alves, JV; Assis, VO; Awata, WMC; Ficher, SP; Gonzaga, NA; Tirapelli, CR; Tostes, RC, 2021) |
| "Obesity is a global health threat and a risk factor for several metabolic conditions." | 1.62 | Obese ( Arellanes-Licea, EDC; Carmona-Castro, A; Díaz-Muñoz, M; Miranda-Anaya, M; Pérez-Mendoza, M, 2021) |
| "Melatonin treatment caused a significant reduction in infarct size in hearts from both control and diet groups." | 1.56 | Mitochondrial Oxidative Phosphorylation Function and Mitophagy in Ischaemic/Reperfused Hearts from Control and High-Fat Diet Rats: Effects of Long-Term Melatonin Treatment. ( Dhanabalan, K; Huisamen, B; Lochner, A; Mzezewa, S, 2020) |
| "Melatonin is a potent antioxidant and improves inflammatory processes and energy metabolism." | 1.51 | Melatonin Supplementation Attenuates the Pro-Inflammatory Adipokines Expression in Visceral Fat from Obese Mice Induced by A High-Fat Diet. ( Alonso-Vale, MIC; Antraco, VJ; Cruz, MM; de Sa, RDCDC; Farias, TDSM; Paixao, RID; Simão, JJ, 2019) |
| "This study investigated the ameliorative role of melatonin (MLT) and the effects of a long-term intake of high-fructose corn syrup (HFCS) on the male reproductive system." | 1.51 | The effects of high-fructose corn syrup consumption on testis physiopathology-The ameliorative role of melatonin. ( Aslankoc, R; Ozmen, O, 2019) |
| "Melatonin acts as an antioxidant and prevents oxidative stress-induced changes in cytotrophoblasts." | 1.48 | Melatonin Improves Mitochondrial Respiration in Syncytiotrophoblasts From Placentas of Obese Women. ( Ireland, KE; Maloyan, A; Myatt, L, 2018) |
| "Leptin is an adipokine secreted in a manner dependent on the circadian rhythm that ultimately reduces food intake." | 1.48 | Melatonin Prevents the Harmful Effects of Obesity on the Brain, Including at the Behavioral Level. ( Bermejo-Millo, JC; Boga, JA; Caballero, B; Coto-Montes, A; de Luxán-Delgado, B; Pérez-Martínez, Z; Potes, Y; Rubio-González, A; Solano, JJ; Vega-Naredo, I, 2018) |
| "Excess weight and obesity are severe public health threats worldwide." | 1.46 | Melatonin prevents obesity through modulation of gut microbiota in mice. ( Hong, F; Jia, L; Jin, X; Wang, J; Wang, S; Xu, P; Xue, T; Zhai, Y, 2017) |
| "Obesity is a common risk factor for non-alcoholic fatty liver disease (NAFLD)." | 1.43 | Hepatic Macrosteatosis Is Partially Converted to Microsteatosis by Melatonin Supplementation in ob/ob Mice Non-Alcoholic Fatty Liver Disease. ( Aleksic, M; Favero, G; Golic, I; Korac, A; Lavazza, A; Rezzani, R; Rodella, LF; Stacchiotti, A, 2016) |
| "Melatonin treatment alone improved circadian activity rhythms, attenuated induction of β-cell failure, and enhanced glucose tolerance." | 1.43 | Administration of Melatonin and Metformin Prevents Deleterious Effects of Circadian Disruption and Obesity in Male Rats. ( Hoang, J; Matveyenko, AV; Nguyen, A; Rakshit, K; Thomas, AP; Vongbunyong, K, 2016) |
| "Melatonin treatment to ZDF rats decreases serum levels of ALT (P < 0." | 1.42 | Melatonin reduces hepatic mitochondrial dysfunction in diabetic obese rats. ( Abdo, W; Agil, A; El-Hammadi, M; Fernández-Vázquez, G; Jiménez-Aranda, A; Reiter, RJ; Tassi, M, 2015) |
| "Obesity is a common and complex health problem, which impacts crucial organs; it is also considered an independent risk factor for chronic kidney disease." | 1.40 | Mitochondrial and metabolic dysfunction in renal convoluted tubules of obese mice: protective role of melatonin. ( Favero, G; Giugno, L; Lavazza, A; Reiter, RJ; Rezzani, R; Rodella, LF; Stacchiotti, A, 2014) |
| "Melatonin has a known influence on the sleep and wake rhythm." | 1.39 | Melatonin and omentin: influence factors in the obstructive sleep apnoea syndrome? ( Brzozowski, T; Fuchs, FS; Hildner, KM; Konturek, PC; Neurath, MF; Targosz, A; Zirlik, S, 2013) |
| "In Japan, obesity is defined by a BMI of 25 kg/m² or over; 28." | 1.39 | Seasonal differences in melatonin concentrations and heart rates during sleep in obese subjects in Japan. ( Inukai, Y; Iwase, S; Kanikowska, D; Nishimura, N; Sato, M; Shimizu, Y; Sugenoya, J, 2013) |
| "Melatonin treatment did not influence plasma levels of these antioxidant minerals (Cu, Zn, Fe, and Mn) in ZDF groups (M-ZDF versus C-ZDF group) and ZL (M-ZL versus C-ZL group) rats with the exception of Zn, whose mean plasma level was lower in the M-ZL versus C-ZL group." | 1.39 | Antioxidant activity of melatonin in diabetes in relation to the regulation and levels of plasma Cu, Zn, Fe, Mn, and Se in Zucker diabetic fatty rats. ( Agil, A; Blanca-Herrera, RM; Navarro-Alarcon, M; Ruiz-Ojeda, FJ, 2013) |
| "Melatonin treatment reduced the BW gain, visceral adiposity, blood TRIG, serum insulin, homeostatic model assessment index and thiobarbituric acid reactive substances in the DIO group." | 1.37 | Chronic melatonin consumption prevents obesity-related metabolic abnormalities and protects the heart against myocardial ischemia and reperfusion injury in a prediabetic model of diet-induced obesity. ( Blackhurst, D; Du Toit, EF; Lochner, A; Marais, D; Nduhirabandi, F, 2011) |
| "Melatonin has several oncostatic properties, including possible anti-estrogenic and anti-aromatase activity, and seems to be linked with fat metabolism." | 1.34 | Night shift work and the risk of endometrial cancer. ( Hankinson, SE; Schernhammer, ES; Viswanathan, AN, 2007) |
| "Although obesity has been reported to be associated with leptin "resistance," it is unclear whether obesity alters the cardiovascular and metabolic effects of chronic MC3/4-R activation." | 1.33 | Does obesity induce resistance to the long-term cardiovascular and metabolic actions of melanocortin 3/4 receptor activation? ( Hall, JE; Kuo, JJ; Liu, J; Silva, AA; Tallam, LS, 2006) |
| "Melatonin levels were significantly lower in patients with insomnia and obese postmenopausal females than in controls." | 1.31 | Melatonin in postmenopausal females. ( Blaicher, W; Gruber, DM; Huber, JC; Imhof, MH; Sator, MO; Schneeberger, C; Speck, E, 2000) |
| "Melatonin was measured in the serum and urine before and after 1 hr of bright light (350 cd/m2)." | 1.29 | Obesity treated with phototherapy: four case studies. ( Boman, K; Bylesjö, EI; Wetterberg, L, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (4.79) | 18.7374 |
| 1990's | 9 (5.39) | 18.2507 |
| 2000's | 16 (9.58) | 29.6817 |
| 2010's | 76 (45.51) | 24.3611 |
| 2020's | 58 (34.73) | 2.80 |
| Authors | Studies |
|---|---|
| Oladele, CA | 1 |
| Akintayo, CO | 3 |
| Badejogbin, OC | 2 |
| Oniyide, AA | 3 |
| Omoaghe, AO | 1 |
| Agunbiade, TB | 2 |
| Olaniyi, KS | 3 |
| Suriagandhi, V | 2 |
| Nachiappan, V | 2 |
| Primack, C | 1 |
| Pivonello, C | 1 |
| Negri, M | 1 |
| Patalano, R | 1 |
| Amatrudo, F | 1 |
| Montò, T | 1 |
| Liccardi, A | 2 |
| Graziadio, C | 1 |
| Muscogiuri, G | 7 |
| Pivonello, R | 1 |
| Colao, A | 7 |
| Obayemi, MJ | 1 |
| Aturamu, A | 2 |
| Atuma, CL | 2 |
| Saidi, AO | 2 |
| Mahmud, H | 2 |
| Choi, Y | 2 |
| Nakamura, Y | 1 |
| Akazawa, N | 1 |
| Park, I | 1 |
| Kwak, HB | 1 |
| Tokuyama, K | 1 |
| Maeda, S | 1 |
| Guan, Q | 1 |
| Wang, Z | 1 |
| Cao, J | 1 |
| Dong, Y | 1 |
| Chen, Y | 1 |
| Andreeva, EN | 2 |
| Grigoryan, OR | 2 |
| Absatarova, YS | 2 |
| Sheremetyeva, EV | 2 |
| Mikheev, RK | 2 |
| Sabinari, IW | 1 |
| Singhanat, K | 1 |
| Apaijai, N | 1 |
| Sumneang, N | 1 |
| Maneechote, C | 1 |
| Arunsak, B | 1 |
| Chunchai, T | 1 |
| Chattipakorn, SC | 1 |
| Chattipakorn, N | 1 |
| Zhang, B | 1 |
| Chen, T | 1 |
| Cao, M | 1 |
| Yuan, C | 1 |
| Reiter, RJ | 11 |
| Zhao, Z | 1 |
| Zhao, Y | 1 |
| Chen, L | 1 |
| Fan, W | 1 |
| Wang, X | 1 |
| Zhou, X | 1 |
| Li, C | 1 |
| Promsan, S | 2 |
| Thongnak, L | 1 |
| Pengrattanachot, N | 1 |
| Phengpol, N | 1 |
| Sutthasupha, P | 1 |
| Lungkaphin, A | 2 |
| McHill, AW | 3 |
| Brown, LS | 1 |
| Phillips, AJK | 1 |
| Barger, LK | 2 |
| Garaulet, M | 5 |
| Scheer, FAJL | 1 |
| Klerman, EB | 2 |
| Mansouri, S | 1 |
| Salari, AA | 1 |
| Abedi, A | 1 |
| Mohammadi, P | 1 |
| Amani, M | 1 |
| Zhao, L | 1 |
| Hutchison, AT | 1 |
| Liu, B | 2 |
| Wittert, GA | 1 |
| Thompson, CH | 1 |
| Nguyen, L | 1 |
| Au, J | 1 |
| Vincent, A | 1 |
| Manoogian, ENC | 1 |
| Le, HD | 1 |
| Williams, AE | 1 |
| Banks, S | 1 |
| Panda, S | 1 |
| Heilbronn, LK | 1 |
| Poggiogalle, E | 1 |
| Barrea, L | 6 |
| Tarsitano, MG | 1 |
| Garifalos, F | 1 |
| Pugliese, G | 2 |
| Savastano, S | 6 |
| Diez-Echave, P | 1 |
| Vezza, T | 1 |
| Algieri, F | 1 |
| Ruiz-Malagón, AJ | 1 |
| Hidalgo-García, L | 1 |
| García, F | 1 |
| Morón, R | 1 |
| Sánchez, M | 1 |
| Toral, M | 1 |
| Romero, M | 1 |
| Duarte, J | 1 |
| Garrido-Mesa, J | 1 |
| Rodríguez-Cabezas, ME | 1 |
| Rodríguez-Nogales, A | 1 |
| Gálvez, J | 1 |
| Hu, S | 1 |
| Liu, X | 1 |
| Wang, Y | 3 |
| Zhang, R | 1 |
| Wei, S | 1 |
| Xu, L | 2 |
| Li, D | 1 |
| Li, H | 1 |
| Zhang, O | 1 |
| Huang, Y | 1 |
| Shao, H | 1 |
| Cai, S | 1 |
| Zhu, Y | 1 |
| Jin, S | 1 |
| Ding, C | 1 |
| Hegazy, HA | 1 |
| Abo-ElMatty, DM | 1 |
| Farid, O | 1 |
| Saleh, S | 1 |
| Ghattas, MH | 1 |
| Omar, NN | 1 |
| Verde, L | 3 |
| Vetrani, C | 3 |
| Docimo, A | 3 |
| de Alteriis, G | 3 |
| Maity, J | 3 |
| Dey, T | 3 |
| Banerjee, A | 3 |
| Chattopadhyay, A | 3 |
| Das, AR | 3 |
| Bandyopadhyay, D | 3 |
| Ajackson, M | 2 |
| Nagagata, BA | 2 |
| Marcondes-de-Castro, IA | 2 |
| Mandarim-de-Lacerda, CA | 2 |
| Aguila, MB | 2 |
| Qin, X | 1 |
| Fu, Y | 1 |
| Fan, J | 1 |
| Liu, P | 1 |
| Zhang, Y | 1 |
| Jiang, T | 1 |
| Zheng, Q | 1 |
| Fernández-Mateos, P | 3 |
| Cano-Barquilla, P | 1 |
| Jiménez-Ortega, V | 4 |
| Virto, L | 3 |
| Pérez-Miguelsanz, J | 1 |
| Esquifino, AI | 5 |
| Pereira, GDAV | 1 |
| Morais, TC | 2 |
| França, EL | 2 |
| Daboin, BEG | 1 |
| Bezerra, IMP | 1 |
| Pessoa, RS | 2 |
| de Quental, OB | 2 |
| Honório-França, AC | 2 |
| Abreu, LC | 1 |
| Zilli Vieira, CL | 1 |
| Koutrakis, P | 1 |
| Liu, M | 1 |
| Gottlieb, DJ | 1 |
| Garshick, E | 1 |
| Yawoot, N | 2 |
| Sengking, J | 1 |
| Govitrapong, P | 4 |
| Tocharus, C | 2 |
| Tocharus, J | 2 |
| Hsu, LW | 1 |
| Chien, YW | 3 |
| Dehdari Ebrahimi, N | 1 |
| Sadeghi, A | 1 |
| Ala, M | 1 |
| Ebrahimi, F | 1 |
| Pakbaz, S | 1 |
| Azarpira, N | 1 |
| Al-Rawaf, HA | 1 |
| Gabr, SA | 1 |
| Iqbal, A | 1 |
| Alghadir, AH | 1 |
| Ku, H | 1 |
| Kim, Y | 1 |
| Kim, AL | 1 |
| Lee, G | 1 |
| Kim, B | 1 |
| Wilson, JB | 1 |
| Epstein, M | 1 |
| Lopez, B | 1 |
| Brown, AK | 1 |
| Lutfy, K | 1 |
| Friedman, TC | 1 |
| Farias, TDSM | 1 |
| Paixao, RID | 1 |
| Cruz, MM | 1 |
| de Sa, RDCDC | 1 |
| Simão, JJ | 1 |
| Antraco, VJ | 1 |
| Alonso-Vale, MIC | 1 |
| Fujimori, M | 1 |
| de Abreu, LC | 1 |
| Yue, S | 1 |
| Zhao, D | 1 |
| Peng, C | 1 |
| Tan, C | 1 |
| Wang, Q | 2 |
| Gong, J | 1 |
| Tümentemur, G | 1 |
| Altunkaynak, BZ | 2 |
| Kaplan, S | 2 |
| Lopez-Minguez, J | 2 |
| Gómez-Abellán, P | 2 |
| Imenshahidi, M | 1 |
| Karimi, G | 1 |
| Hosseinzadeh, H | 1 |
| Dhanabalan, K | 1 |
| Mzezewa, S | 1 |
| Huisamen, B | 2 |
| Lochner, A | 4 |
| El-Missiry, MA | 1 |
| El-Missiry, ZMA | 1 |
| Othman, AI | 1 |
| Tung, YT | 1 |
| Chiang, PC | 1 |
| Chen, YL | 1 |
| Ramirez, AVG | 1 |
| Filho, DR | 1 |
| de Sá, LBPC | 1 |
| Al-Rawi, N | 1 |
| Madkour, M | 1 |
| Jahrami, H | 1 |
| Salahat, D | 1 |
| Alhasan, F | 1 |
| BaHammam, A | 1 |
| Al-Islam Faris, M | 1 |
| Miller, MA | 1 |
| Cappuccio, FP | 1 |
| Genario, R | 1 |
| Cipolla-Neto, J | 3 |
| Bueno, AA | 1 |
| Santos, HO | 1 |
| Laudisio, D | 2 |
| Aprano, S | 1 |
| Castellucci, B | 1 |
| Gonzaga, NA | 1 |
| Awata, WMC | 1 |
| Ficher, SP | 1 |
| Assis, VO | 1 |
| Alves, JV | 1 |
| Tostes, RC | 1 |
| Tirapelli, CR | 1 |
| Arellanes-Licea, EDC | 1 |
| Pérez-Mendoza, M | 1 |
| Carmona-Castro, A | 1 |
| Díaz-Muñoz, M | 1 |
| Miranda-Anaya, M | 1 |
| Ponomareva, TA | 1 |
| Pawlikowski, M | 1 |
| Winczyk, K | 1 |
| Huang, X | 1 |
| Chen, X | 1 |
| Zhao, S | 1 |
| Hou, J | 1 |
| Huang, L | 1 |
| Xu, J | 1 |
| Wang, W | 1 |
| He, M | 1 |
| Shen, O | 1 |
| Zhang, J | 1 |
| Dufoo-Hurtado, E | 1 |
| Olvera-Bautista, R | 1 |
| Wall-Medrano, A | 1 |
| Loarca-Piña, G | 1 |
| Campos-Vega, R | 1 |
| Cheng, WY | 1 |
| Lam, KL | 1 |
| Li, X | 2 |
| Kong, AP | 1 |
| Cheung, PC | 1 |
| Novais, AA | 1 |
| Chuffa, LGA | 1 |
| Zuccari, DAPC | 1 |
| Mohammadi, S | 1 |
| Rastmanesh, R | 2 |
| Jahangir, F | 1 |
| Amiri, Z | 1 |
| Djafarian, K | 1 |
| Mohsenpour, MA | 1 |
| Hassanipour, S | 1 |
| Ghaffarian-Bahraman, A | 1 |
| Ireland, KE | 1 |
| Maloyan, A | 1 |
| Myatt, L | 1 |
| Saxena, R | 1 |
| Bandín, C | 1 |
| Scheer, FA | 2 |
| Onger, ME | 1 |
| Geuna, S | 1 |
| Türkmen, AP | 1 |
| Muratori, L | 1 |
| Altun, G | 1 |
| Wongchitrat, P | 2 |
| Klosen, P | 1 |
| Pannengpetch, S | 1 |
| Kitidee, K | 1 |
| Isarankura-Na-Ayudhya, C | 1 |
| Han, L | 1 |
| Wang, H | 1 |
| Li, L | 2 |
| Ge, J | 1 |
| Phillips, AJ | 1 |
| Czeisler, CA | 1 |
| Keating, L | 1 |
| Yee, K | 1 |
| Rubio-González, A | 1 |
| Bermejo-Millo, JC | 1 |
| de Luxán-Delgado, B | 1 |
| Potes, Y | 1 |
| Pérez-Martínez, Z | 1 |
| Boga, JA | 1 |
| Vega-Naredo, I | 1 |
| Caballero, B | 1 |
| Solano, JJ | 1 |
| Coto-Montes, A | 1 |
| Szewczyk-Golec, K | 2 |
| Rajewski, P | 1 |
| Gackowski, M | 1 |
| Mila-Kierzenkowska, C | 1 |
| Wesołowski, R | 1 |
| Sutkowy, P | 1 |
| Pawłowska, M | 1 |
| Woźniak, A | 2 |
| Malazonia, A | 1 |
| Zerekidze, T | 1 |
| Vekua, N | 1 |
| Chkheidze, N | 1 |
| Asatiani, K | 1 |
| Anagnostou, E | 1 |
| Fernández Vázquez, G | 1 |
| Agil, A | 6 |
| González-González, A | 1 |
| Mediavilla, MD | 2 |
| Sánchez-Barceló, EJ | 2 |
| Prado, NJ | 1 |
| Ferder, L | 1 |
| Manucha, W | 1 |
| Diez, ER | 1 |
| Haugen, HJ | 2 |
| Cano, P | 3 |
| González, J | 2 |
| Sanz, M | 2 |
| Montalbano, G | 1 |
| Mania, M | 1 |
| Abbate, F | 1 |
| Navarra, M | 1 |
| Guerrera, MC | 1 |
| Laura, R | 1 |
| Vega, JA | 1 |
| Levanti, M | 1 |
| Germanà, A | 1 |
| Liu, Y | 1 |
| Li, LN | 1 |
| Guo, S | 1 |
| Zhao, XY | 1 |
| Liu, YZ | 1 |
| Liang, C | 1 |
| Tu, S | 1 |
| Wang, D | 1 |
| Dong, JZ | 1 |
| Gao, L | 1 |
| Yang, HB | 1 |
| Annunziata, G | 1 |
| Di Somma, C | 1 |
| Egan Benova, T | 1 |
| Viczenczova, C | 1 |
| Szeiffova Bacova, B | 1 |
| Knezl, V | 1 |
| Dosenko, V | 1 |
| Rauchova, H | 1 |
| Zeman, M | 1 |
| Tribulova, N | 1 |
| Simon, SL | 2 |
| Behn, CD | 1 |
| Cree-Green, M | 2 |
| Kaar, JL | 2 |
| Pyle, L | 2 |
| Hawkins, SMM | 1 |
| Rahat, H | 2 |
| Garcia-Reyes, Y | 2 |
| Wright, KP | 3 |
| Nadeau, KJ | 2 |
| Karamitri, A | 2 |
| Jockers, R | 2 |
| Yang, TH | 1 |
| Chen, YC | 1 |
| Ou, TH | 1 |
| McWhirter, L | 1 |
| Diniz Behn, C | 1 |
| Bubar, KM | 1 |
| Carreau, AM | 1 |
| Chen, C | 1 |
| Ling, MY | 1 |
| Lin, FH | 1 |
| Lv, ZM | 1 |
| Aslankoc, R | 1 |
| Ozmen, O | 1 |
| Xu, Z | 1 |
| You, W | 1 |
| Liu, J | 2 |
| Shan, T | 1 |
| Zanuto, R | 1 |
| Siqueira-Filho, MA | 1 |
| Caperuto, LC | 1 |
| Bacurau, RF | 1 |
| Hirata, E | 1 |
| Peliciari-Garcia, RA | 1 |
| do Amaral, FG | 1 |
| Marçal, AC | 1 |
| Ribeiro, LM | 1 |
| Camporez, JP | 1 |
| Carpinelli, AR | 1 |
| Bordin, S | 1 |
| Carvalho, CR | 1 |
| Favero, G | 5 |
| Lonati, C | 1 |
| Giugno, L | 2 |
| Castrezzati, S | 2 |
| Rodella, LF | 5 |
| Rezzani, R | 5 |
| Eisenstein, M | 1 |
| Renault, N | 1 |
| Clement, N | 1 |
| Guillaume, JL | 1 |
| Zirlik, S | 1 |
| Hildner, KM | 1 |
| Targosz, A | 1 |
| Neurath, MF | 1 |
| Fuchs, FS | 1 |
| Brzozowski, T | 1 |
| Konturek, PC | 1 |
| Majumdar, AS | 1 |
| Giri, PR | 1 |
| Pai, SA | 1 |
| Amaral, FG | 1 |
| Afeche, SC | 1 |
| Tan, DX | 3 |
| Fonken, LK | 1 |
| Nelson, RJ | 1 |
| Agabiti-Rosei, C | 1 |
| De Ciuceis, C | 1 |
| Rossini, C | 1 |
| Porteri, E | 1 |
| Withers, SB | 1 |
| Heagerty, AM | 1 |
| Agabiti-Rosei, E | 1 |
| Rizzoni, D | 1 |
| Winiarska, K | 1 |
| Focht, D | 1 |
| Sierakowski, B | 1 |
| Lewandowski, K | 1 |
| Orlowska, M | 1 |
| Usarek, M | 1 |
| Tan, E | 1 |
| Scott, EM | 1 |
| McFadden, E | 1 |
| Jones, ME | 1 |
| Schoemaker, MJ | 1 |
| Ashworth, A | 1 |
| Swerdlow, AJ | 1 |
| Bonnefont-Rousselot, D | 1 |
| Corbalán-Tutau, MD | 1 |
| Madrid, JA | 1 |
| Canteras, M | 1 |
| Ordovás, JM | 1 |
| Mesri Alamdari, N | 1 |
| Mahdavi, R | 1 |
| Roshanravan, N | 1 |
| Lotfi Yaghin, N | 1 |
| Ostadrahimi, AR | 1 |
| Faramarzi, E | 1 |
| Sieck, G | 1 |
| Nduhirabandi, F | 3 |
| Strijdom, H | 1 |
| Blackhurst, D | 2 |
| Navarro-Alarcón, M | 4 |
| Ruiz-Ojeda, FJ | 2 |
| Blanca-Herrera, RM | 2 |
| A-Serrano, MM | 1 |
| Acuña-Castroviejo, D | 1 |
| Fernández-Vázquez, G | 2 |
| Jenwitheesuk, A | 1 |
| Nopparat, C | 1 |
| Mukda, S | 1 |
| Stacchiotti, A | 3 |
| Lavazza, A | 2 |
| Trufakin, VA | 1 |
| Shurlygina, AV | 1 |
| Dushkin, MI | 1 |
| Khrapova, MV | 1 |
| Michurina, SV | 2 |
| Mel'nikova, EV | 1 |
| Panteleeva, NG | 1 |
| Tenditnik, MV | 1 |
| Melanson, EL | 1 |
| Higgins, J | 1 |
| Connick, E | 1 |
| Moehlman, TM | 1 |
| Stothard, ER | 1 |
| El-Hammadi, M | 1 |
| Jiménez-Aranda, A | 1 |
| Tassi, M | 1 |
| Abdo, W | 1 |
| Howland, RH | 1 |
| Elmahallawy, EK | 1 |
| Rodríguez-Ferrer, JM | 1 |
| Adem, A | 1 |
| Bastaki, SM | 1 |
| Al-Abbadi, I | 1 |
| Fino Solano, YA | 1 |
| Bonomini, F | 1 |
| Albanese, M | 1 |
| Golic, I | 1 |
| Aleksic, M | 1 |
| Korac, A | 1 |
| Cardinali, DP | 4 |
| Hardeland, R | 1 |
| Thomas, AP | 1 |
| Hoang, J | 1 |
| Vongbunyong, K | 1 |
| Nguyen, A | 1 |
| Rakshit, K | 1 |
| Matveyenko, AV | 1 |
| Grosshans, M | 1 |
| Vollmert, C | 1 |
| Vollstaedt-Klein, S | 1 |
| Nolte, I | 1 |
| Schwarz, E | 1 |
| Wagner, X | 1 |
| Leweke, M | 1 |
| Mutschler, J | 1 |
| Kiefer, F | 1 |
| Bumb, JM | 1 |
| Ishchenko, IY | 1 |
| Arkhipov, SA | 1 |
| Klimontov, VV | 1 |
| Rachkovskaya, LN | 1 |
| Konenkov, VI | 1 |
| Zavyalov, EL | 1 |
| Xu, P | 1 |
| Wang, J | 1 |
| Hong, F | 1 |
| Wang, S | 1 |
| Jin, X | 1 |
| Xue, T | 1 |
| Jia, L | 1 |
| Zhai, Y | 1 |
| Kapoor, S | 1 |
| Viswanathan, AN | 2 |
| Schernhammer, ES | 2 |
| She, M | 1 |
| Deng, X | 1 |
| Guo, Z | 1 |
| Laudon, M | 1 |
| Hu, Z | 1 |
| Liao, D | 1 |
| Hu, X | 1 |
| Luo, Y | 1 |
| Shen, Q | 1 |
| Su, Z | 1 |
| Yin, W | 1 |
| Manchester, LC | 1 |
| Fuentes-Broto, L | 1 |
| Paredes, SD | 1 |
| Ríos-Lugo, MJ | 1 |
| Fernández-Mateos, MP | 1 |
| Scacchi, PA | 1 |
| Du Toit, EF | 2 |
| Marais, D | 1 |
| Ruiz, R | 1 |
| Abuhamadah, S | 1 |
| El-Mir, MY | 1 |
| Vázquez, GF | 1 |
| Korkmaz, A | 1 |
| Ma, S | 1 |
| Cizza, G | 2 |
| Requena, M | 1 |
| Galli, G | 1 |
| de Jonge, L | 1 |
| Pagano, ES | 1 |
| Scacchi Bernasconi, PA | 1 |
| Reynoso, R | 1 |
| Scacchi, P | 1 |
| de Bruin, PF | 1 |
| Mäntele, S | 1 |
| Otway, DT | 1 |
| Middleton, B | 1 |
| Bretschneider, S | 1 |
| Wright, J | 1 |
| Robertson, MD | 1 |
| Skene, DJ | 1 |
| Johnston, JD | 1 |
| Lucassen, EA | 1 |
| Rother, KI | 1 |
| Sato, M | 2 |
| Kanikowska, D | 1 |
| Iwase, S | 1 |
| Shimizu, Y | 1 |
| Nishimura, N | 1 |
| Inukai, Y | 1 |
| Sugenoya, J | 1 |
| Obayashi, K | 1 |
| Saeki, K | 1 |
| Iwamoto, J | 1 |
| Okamoto, N | 1 |
| Tomioka, K | 1 |
| Nezu, S | 1 |
| Ikada, Y | 1 |
| Kurumatani, N | 1 |
| Müller, HL | 2 |
| Handwerker, G | 2 |
| Wollny, B | 1 |
| Faldum, A | 2 |
| Sörensen, N | 2 |
| Prunet-Marcassus, B | 1 |
| Desbazeille, M | 1 |
| Bros, A | 1 |
| Louche, K | 1 |
| Delagrange, P | 2 |
| Renard, P | 2 |
| Casteilla, L | 2 |
| Pénicaud, L | 1 |
| Ferrari, E | 3 |
| Magri, F | 1 |
| Pontiggia, B | 1 |
| Rondanelli, M | 1 |
| Fioravanti, M | 1 |
| Solerte, SB | 1 |
| Severgnini, S | 1 |
| Adam, CL | 1 |
| Mercer, JG | 1 |
| Silva, AA | 1 |
| Kuo, JJ | 1 |
| Tallam, LS | 1 |
| Hall, JE | 1 |
| Fideleff, HL | 1 |
| Boquete, H | 1 |
| Fideleff, G | 1 |
| Albornoz, L | 1 |
| Pérez Lloret, S | 1 |
| Suarez, M | 1 |
| Honfi, M | 1 |
| Gebhardt, U | 1 |
| Emser, A | 1 |
| Kolb, R | 1 |
| Raskind, MA | 1 |
| Burke, BL | 1 |
| Crites, NJ | 1 |
| Tapp, AM | 1 |
| Rasmussen, DD | 1 |
| Hussein, MR | 1 |
| Ahmed, OG | 1 |
| Hassan, AF | 1 |
| Ahmed, MA | 1 |
| Sanchez-Mateos, S | 1 |
| Alonso-Gonzalez, C | 1 |
| Gonzalez, A | 1 |
| Martinez-Campa, CM | 1 |
| Cos, S | 1 |
| Hankinson, SE | 1 |
| Wade, GN | 1 |
| Bartness, TJ | 2 |
| Tamarkin, L | 1 |
| Abastillas, P | 1 |
| Chen, HC | 1 |
| McNemar, A | 1 |
| Sidbury, JB | 1 |
| Roush, W | 1 |
| Le Gouic, S | 1 |
| Atgié, C | 1 |
| Nibbelink, M | 1 |
| Hanoun, N | 1 |
| Lesieur, D | 1 |
| Guardiola-Lemaitre, B | 1 |
| Ambid, L | 1 |
| Bylesjö, EI | 1 |
| Boman, K | 1 |
| Wetterberg, L | 3 |
| Birketvedt, GS | 1 |
| Florholmen, J | 1 |
| Sundsfjord, J | 1 |
| Osterud, B | 1 |
| Dinges, D | 1 |
| Bilker, W | 1 |
| Stunkard, A | 1 |
| Blaicher, W | 2 |
| Imhof, MH | 2 |
| Gruber, DM | 2 |
| Schneeberger, C | 2 |
| Sator, MO | 2 |
| Huber, JC | 2 |
| Speck, E | 1 |
| Ostrowska, Z | 1 |
| Kos-Kudla, B | 1 |
| Marek, B | 1 |
| Swietochowska, E | 1 |
| Górski, J | 1 |
| Demas, GE | 1 |
| Song, CK | 1 |
| Röjdmark, S | 2 |
| Rössner, S | 2 |
| Berg, A | 1 |
| Fraschini, F | 2 |
| Brambilla, F | 2 |
| Foppa, S | 1 |
| Bossolo, PA | 1 |
| Comis, S | 1 |
| Esposti, G | 1 |
| Licini, V | 1 |
| Himms-Hagen, J | 1 |
| Willig, RP | 1 |
| Braun, W | 1 |
| Commentz, JC | 1 |
| Stahnke, N | 1 |
| Rosenthal, NE | 1 |
| Genhart, M | 1 |
| Jacobsen, FM | 1 |
| Skwerer, RG | 1 |
| Wehr, TA | 1 |
| Lang, U | 1 |
| Theintz, G | 1 |
| Rivest, RW | 1 |
| Sizonenko, PC | 1 |
| Bailey, CJ | 1 |
| Atkins, TW | 1 |
| Matty, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Obstructive Sleep Apnea in Patients With Long COVID-19 Fatigue: a Multicentre Prospective Cohort Study[NCT05290350] | 300 participants (Anticipated) | Observational | 2022-03-10 | Recruiting | |||
| Glucose Tolerance, Meal Timing and MTNR1B in a Mediterranean Population[NCT03003936] | 280 participants (Actual) | Interventional | 2014-12-31 | Completed | |||
| Effects of Time-Restricted Fasting on the Postprandial Glycemic Responses in Chinese Adults: A Randomized Crossover Study[NCT05913635] | 36 participants (Actual) | Interventional | 2022-09-01 | Active, not recruiting | |||
| Effect of a Chrono Nutrition Intervention on Insulin Resistance in Adults With Type 2 Diabetes[NCT06163248] | 40 participants (Anticipated) | Interventional | 2024-01-01 | Enrolling by invitation | |||
| Multi-scale Modeling of Sleep Behaviors in Social Networks[NCT02846077] | 729 participants (Actual) | Observational | 2013-09-30 | Completed | |||
| Assessment of Hepatic Glucose and Fat Regulation in Overweight Adolescent Girls[NCT02157974] | Phase 2/Phase 3 | 92 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| Investigating the Relationship Between Circadian Phase and Insulin Resistance in Obese Adolescents[NCT02585830] | 25 participants (Actual) | Observational | 2015-10-31 | Completed | |||
| Melatonin and Essential Arterial Hypertension[NCT05257291] | Phase 2 | 23 participants (Actual) | Interventional | 2018-02-02 | Active, not recruiting | ||
| Circadian Disturbances in People With Mental Disease[NCT05413486] | 86 participants (Anticipated) | Observational | 2022-04-04 | Recruiting | |||
| Meal Timing, Genetics and Weight Loss in a Mediterranean Population[NCT02829619] | 5,788 participants (Anticipated) | Observational | 2008-01-31 | Recruiting | |||
| A Triple Blinded Randomized Controlled Trial of Oral Melatonin in Elevated Blood Pressure Individual (MRCTEBP)[NCT03764020] | Phase 3 | 320 participants (Anticipated) | Interventional | 2019-06-01 | Not yet recruiting | ||
| Behavioral Chronotype: Impact on Sleep and Metabolism[NCT03647306] | 200 participants (Anticipated) | Interventional | 2018-02-02 | Active, not recruiting | |||
| Examining the Impact of a 12-week Worksite Exercise Training Intervention on Mental, Metabolic, Physical, Spiritual, and Occupational Well-being Among Acute Care Nurses: A Randomized, Controlled Mixed Methods Pilot Study[NCT05966805] | 20 participants (Anticipated) | Interventional | 2023-09-13 | Recruiting | |||
| Effect of the Administration of Melatonin and Metformin on Glycemic Control, Genotoxicity and Cytotoxicity Markers in Patients With Prediabetes: Pilot Study[NCT03848533] | Phase 2 | 42 participants (Anticipated) | Interventional | 2019-08-22 | Recruiting | ||
| Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia[NCT00595504] | Phase 4 | 25 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Phase 2 Study of Melatonin Adjunct to Olanzapine for Prevention of Olanzapine-associated Metabolic Side Effects.[NCT01593774] | Phase 2 | 36 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine and Melatonin Dose Finding for the Correction of the Metabolic Abnormality[NCT00512070] | 20 participants (Anticipated) | Interventional | 2007-07-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
~1mL saliva was collected at 30- to 60- minute intervals in dim light (<5 lux in the angle of gaze, approximately the light level of candlelight or civil twilight) from approximately 5pm until noon the next day. Dim light melatonin onset (DLMOn) was defined as the linear interpolated clock time at which evening salivary melatonin concentrations increased and remained above a threshold of 3pg/mL. Melatonin offset (DLMOff) was the linear interpolated clock time at which salivary melatonin concentrations fell below this threshold. Later DLMOn and DLMOff are indicative of a later circadian rhythm. (NCT02585830)
Timeframe: 1 day
| Intervention | decimal hours (Mean) | |
|---|---|---|
| Dim Light Melatonin Onset | Dim Light Melatonin Offset | |
| Observation | 21.33 | 8.32 |
After an overnight fast, participants completed an oral glucose tolerance test (OGTT) in the morning. Participants consumed a 75g dextrose drink and serum for glucose and insulin concentrations were collected at baseline and every 30 minutes for 3 hours. The homeostatic model assessment for insulin resistance (HOMA-IR) was calculated as [fasting insulin (μU/ml) x fasting glucose (mmol/l)] / 22.5); lower HOMA-IR indicates better insulin sensitivity. The Matsuda Index was calculated as √10,000 / [[fasting insulin (μU/ml) x fasting glucose (mmol/l)] x [mean OSTT insulin (μU/ml) x mean OSTT glucose (mmol/l)]]; high Matsuda Index indicates better insulin sensitivity. (NCT02585830)
Timeframe: 3 hours
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Homeostatic Model Assessment (HOMA-IR) | Matsuda Index | |
| Observation | 2.9 | 4.93 |
A comparison between the ramelteon group and the placebo group of change in abdominal fat measured by a DEXA scan, assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | g (Mean) |
|---|---|
| Ramelteon | 3934.86 |
| Placebo (Sugar Pill) | 5120.92 |
A comparison between the ramelteon group and the placebo group of change in insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR), assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Ramelteon | 2.4 |
| Placebo (Sugar Pill) | 2.36 |
A comparison between the ramelteon group and the placebo group in change in waist circumference (measured in cm) measured at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | cm (Mean) |
|---|---|
| Ramelteon | 106.09 |
| Placebo (Sugar Pill) | 108.37 |
49 reviews available for melatonin and Obesity
| Article | Year |
|---|---|
Protective Effects of Melatonin against Obesity-Induced by Leptin Resistance.
Topics: Appetite; Circadian Rhythm; Humans; Hypothalamus; Leptin; Melatonin; Obesity | 2022 |
Obesity and Sleep.
Topics: Appetite; Ghrelin; Humans; Leptin; Melatonin; Obesity; Sleep; Sleep Deprivation; Stress, Psychologic | 2021 |
The role of melatonin in the molecular mechanisms underlying metaflammation and infections in obesity: A narrative review.
Topics: Adipokines; Adipose Tissue, Brown; Humans; Inflammation; Melatonin; Obesity | 2022 |
Mechanisms of Melatonin in Obesity: A Review.
Topics: Adipose Tissue; Animals; Circadian Rhythm; Gastrointestinal Microbiome; Humans; Inflammation; Lipid | 2021 |
Exposure to artificial light at night: A common link for obesity and cancer?
Topics: Humans; Light; Light Pollution; Melatonin; Neoplasms; Obesity | 2022 |
Melatonin ameliorates myocardial infarction in obese diabetic individuals: The possible involvement of macrophage apoptotic factors.
Topics: Anti-Inflammatory Agents; Antioxidants; Apoptosis; Cholesterol; Diabetes Mellitus, Type 2; Humans; M | 2023 |
Melatonin ameliorates myocardial infarction in obese diabetic individuals: The possible involvement of macrophage apoptotic factors.
Topics: Anti-Inflammatory Agents; Antioxidants; Apoptosis; Cholesterol; Diabetes Mellitus, Type 2; Humans; M | 2023 |
Melatonin ameliorates myocardial infarction in obese diabetic individuals: The possible involvement of macrophage apoptotic factors.
Topics: Anti-Inflammatory Agents; Antioxidants; Apoptosis; Cholesterol; Diabetes Mellitus, Type 2; Humans; M | 2023 |
Melatonin ameliorates myocardial infarction in obese diabetic individuals: The possible involvement of macrophage apoptotic factors.
Topics: Anti-Inflammatory Agents; Antioxidants; Apoptosis; Cholesterol; Diabetes Mellitus, Type 2; Humans; M | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Protective effects of melatonin against oxidative stress induced by metabolic disorders in the male reproductive system: a systematic review and meta-analysis of rodent models.
Topics: Animals; Body Weight; Diabetes Mellitus; Hyperthyroidism; Infertility, Male; Male; Melatonin; Metabo | 2023 |
The role of Neurochemicals, Stress Hormones and Immune System in the Positive Feedback Loops between Diabetes, Obesity and Depression.
Topics: Adolescent; Depression; Depressive Disorder, Major; Diabetes Mellitus, Type 2; Feedback; Humans; Imm | 2023 |
Timing of Breakfast, Lunch, and Dinner. Effects on Obesity and Metabolic Risk.
Topics: Adipose Tissue; Animals; Blood Glucose; Breakfast; Circadian Rhythm; Feeding Behavior; Female; Gluco | 2019 |
Effects of melatonin on cardiovascular risk factors and metabolic syndrome: a comprehensive review.
Topics: Animals; Antioxidants; Cardiovascular Diseases; Free Radical Scavengers; Heart Disease Risk Factors; | 2020 |
The roles of melatonin on kidney injury in obese and diabetic conditions.
Topics: Adipocytes; Adipose Tissue; Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Cytokines; D | 2020 |
Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of Covid-19.
Topics: Adjuvants, Immunologic; Antioxidants; Antiviral Agents; Betacoronavirus; Clinical Trials as Topic; C | 2020 |
Melatonin and its Relationships with Diabetes and Obesity: A Literature Review.
Topics: Adult; Diabetes Mellitus; Humans; Melatonin; Obesity; Prospective Studies; Randomized Controlled Tri | 2021 |
A systematic review of COVID-19 and obstructive sleep apnoea.
Topics: Comorbidity; Continuous Positive Airway Pressure; COVID-19; Diabetes Mellitus; Humans; Hypertension; | 2021 |
Melatonin supplementation in the management of obesity and obesity-associated disorders: A review of physiological mechanisms and clinical applications.
Topics: Adipose Tissue; Animals; Antioxidants; Dietary Supplements; Glucose; Humans; Insulin Resistance; Lip | 2021 |
Ischemic stroke, obesity, and the anti-inflammatory role of melatonin.
Topics: Animals; Anti-Inflammatory Agents; Encephalitis; Humans; Inflammation; Ischemic Stroke; Melatonin; M | 2021 |
A practical nutritional guide for the management of sleep disturbances in menopause.
Topics: Adult; Aged; Anxiety; Depression; Diet; Female; Humans; Male; Melatonin; Menopause; Middle Aged; Obe | 2021 |
[Analysis of melatonin concentration and its correlation with ovarian disfunction among obese women of reproductive age].
Topics: Female; Humans; Melatonin; Obesity; Ovarian Diseases; Reproduction; Russia | 2021 |
Endocrine and metabolic aspects of COVID-19.
Topics: Aging; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme 2; COVID-19; Diabetes Mellitus; Hu | 2021 |
Exosomes and Melatonin: Where Their Destinies Intersect.
Topics: Animals; Brain Diseases; Colitis; Exosomes; Humans; Kidney Diseases; Liver Diseases; Melatonin; Neop | 2021 |
Clinical trials in autism spectrum disorder: evidence, challenges and future directions.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Aggression; Antipsychotic Agents; Aripipraz | 2018 |
Melatonin: A Molecule for Reducing Breast Cancer Risk.
Topics: Animals; Breast Neoplasms; Environment; Estrogen Receptor Modulators; Female; Humans; Melatonin; Obe | 2018 |
Anti-Inflammatory Effects of Melatonin in Obesity and Hypertension.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Blood Pressure; Humans; Hypertension; Inflammation; | 2018 |
Obesity and sleep disturbance: the chicken or the egg?
Topics: Diet; Endocannabinoids; Energy Metabolism; Exercise; Ghrelin; Humans; Hydrocortisone; Leptin; Melato | 2019 |
Melatonin in type 2 diabetes mellitus and obesity.
Topics: Animals; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Genetic Variation; Genome-Wi | 2019 |
Elucidating the Regulatory Role of Melatonin in Brown, White, and Beige Adipocytes.
Topics: Adipocytes, Beige; Adipocytes, Brown; Adipocytes, White; Adipogenesis; Adiposity; Animals; Body Weig | 2020 |
Minireview: Toward the establishment of a link between melatonin and glucose homeostasis: association of melatonin MT2 receptor variants with type 2 diabetes.
Topics: Amino Acid Sequence; Animals; Diabetes Mellitus, Type 2; Glucose; Humans; Melatonin; Mice; Molecular | 2013 |
Melatonin, energy metabolism, and obesity: a review.
Topics: Adipose Tissue, Brown; Animals; Energy Metabolism; Gene Expression Regulation; Glucose Transporter T | 2014 |
The effects of light at night on circadian clocks and metabolism.
Topics: Animals; Circadian Clocks; Glucocorticoids; Humans; Lighting; Melatonin; Metabolism; Models, Animal; | 2014 |
Circadian rhythms, insulin action, and glucose homeostasis.
Topics: Animals; Blood Glucose; Chronobiology Disorders; Circadian Clocks; Circadian Rhythm; Diet, Carbohydr | 2014 |
Obesity and oxidative stress: potential roles of melatonin as antioxidant and metabolic regulator.
Topics: Animals; Antioxidants; Humans; Melatonin; Metabolic Syndrome; Obesity; Oxidative Stress; Reactive Ox | 2014 |
Living a healthier lifestyle.
Topics: Acute Kidney Injury; Calcium; Humans; Hypoglycemia; Life Style; Melatonin; Obesity | 2014 |
Melatonin and metabolic regulation: a review.
Topics: Animals; Blood Pressure; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Hyperglycemia; M | 2014 |
Melatonin regulates aging and neurodegeneration through energy metabolism, epigenetics, autophagy and circadian rhythm pathways.
Topics: Aging; Animals; Autophagy; Brain; Caloric Restriction; Circadian Rhythm; Diabetes Mellitus; Energy M | 2014 |
Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain.
Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Humans; Liraglutide; Melatonin; Naltrexone; Obesi | 2015 |
Inter-relationships of the chronobiotic, melatonin, with leptin and adiponectin: implications for obesity.
Topics: Adipokines; Adiponectin; Adipose Tissue, White; Animals; Humans; Leptin; Melatonin; Obesity | 2015 |
Inflammaging, Metabolic Syndrome and Melatonin: A Call for Treatment Studies.
Topics: Aging; Animals; Humans; Inflammation Mediators; Melatonin; Metabolic Syndrome; Models, Biological; O | 2017 |
Circulating melatonin and the risk of breast and endometrial cancer in women.
Topics: Aromatase; Breast Neoplasms; Carcinoma; Case-Control Studies; Cell Transformation, Neoplastic; Circa | 2009 |
Significance and application of melatonin in the regulation of brown adipose tissue metabolism: relation to human obesity.
Topics: Adipose Tissue, Brown; Energy Metabolism; Humans; Melatonin; Obesity | 2011 |
Obesity and metabolic syndrome: association with chronodisruption, sleep deprivation, and melatonin suppression.
Topics: Adolescent; Adult; Animals; Child; Chronobiology Disorders; Comorbidity; Disease Models, Animal; Hum | 2012 |
Chronic sleep deprivation and seasonality: implications for the obesity epidemic.
Topics: Adipose Tissue, Brown; Adult; Aged; Animals; Energy Intake; Energy Metabolism; Female; Hibernation; | 2011 |
Disrupted chronobiology of sleep and cytoprotection in obesity: possible therapeutic value of melatonin.
Topics: Animals; Antioxidants; Chronobiology Phenomena; Circadian Rhythm; Cytoprotection; Humans; Melatonin; | 2011 |
Melatonin and the metabolic syndrome: a tool for effective therapy in obesity-associated abnormalities?
Topics: Body Weight; Energy Metabolism; Humans; Insulin Resistance; Melatonin; Metabolic Syndrome; Obesity | 2012 |
Interacting epidemics? Sleep curtailment, insulin resistance, and obesity.
Topics: Adiponectin; Appetite; Diabetes Mellitus; Energy Metabolism; Female; Ghrelin; Glucose; Humans; Insul | 2012 |
Appetite regulation and seasonality: implications for obesity.
Topics: Animals; Appetite Regulation; Body Weight; Energy Metabolism; Humans; Leptin; Melatonin; Obesity; Ph | 2004 |
Seasonal changes in adiposity: the roles of the photoperiod, melatonin and other hormones, and sympathetic nervous system.
Topics: Adipose Tissue; Animals; Brain; Humans; Light; Melatonin; Models, Biological; Obesity; Seasons; Ster | 2002 |
Brown adipose tissue metabolism and thermogenesis.
Topics: Adipose Tissue, Brown; Animals; Body Temperature Regulation; Central Nervous System; Cold Temperatur | 1985 |
Disturbances of appetite and weight regulation in seasonal affective disorder.
Topics: Body Weight; Depression; Dietary Carbohydrates; Feeding and Eating Disorders; Feeding Behavior; Fema | 1987 |
8 trials available for melatonin and Obesity
| Article | Year |
|---|---|
Effects of nocturnal light exposure on circadian rhythm and energy metabolism in healthy adults: A randomized crossover trial.
Topics: Adult; Circadian Rhythm; Cross-Over Studies; Energy Metabolism; Humans; Light; Male; Melatonin; Obes | 2022 |
Therapeutic potential of a single-dose melatonin in the attenuation of cardiac ischemia/reperfusion injury in prediabetic obese rats.
Topics: Animals; Melatonin; Myocardial Reperfusion Injury; Obesity; Prediabetic State; Rats; Rats, Wistar | 2022 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Melatonin Supplementation and Anthropometric Indices: A Randomized Double-Blind Controlled Clinical Trial.
Topics: Adult; Anthropometry; Body Composition; Body Mass Index; Body Weight; Diet, Reducing; Double-Blind M | 2021 |
Late dinner impairs glucose tolerance in MTNR1B risk allele carriers: A randomized, cross-over study.
Topics: Adult; Blood Glucose; Cross-Over Studies; Female; Glucose Tolerance Test; Humans; Meals; Melatonin; | 2018 |
Late dinner impairs glucose tolerance in MTNR1B risk allele carriers: A randomized, cross-over study.
Topics: Adult; Blood Glucose; Cross-Over Studies; Female; Glucose Tolerance Test; Humans; Meals; Melatonin; | 2018 |
Late dinner impairs glucose tolerance in MTNR1B risk allele carriers: A randomized, cross-over study.
Topics: Adult; Blood Glucose; Cross-Over Studies; Female; Glucose Tolerance Test; Humans; Meals; Melatonin; | 2018 |
Late dinner impairs glucose tolerance in MTNR1B risk allele carriers: A randomized, cross-over study.
Topics: Adult; Blood Glucose; Cross-Over Studies; Female; Glucose Tolerance Test; Humans; Meals; Melatonin; | 2018 |
Late dinner impairs glucose tolerance in MTNR1B risk allele carriers: A randomized, cross-over study.
Topics: Adult; Blood Glucose; Cross-Over Studies; Female; Glucose Tolerance Test; Humans; Meals; Melatonin; | 2018 |
Late dinner impairs glucose tolerance in MTNR1B risk allele carriers: A randomized, cross-over study.
Topics: Adult; Blood Glucose; Cross-Over Studies; Female; Glucose Tolerance Test; Humans; Meals; Melatonin; | 2018 |
Late dinner impairs glucose tolerance in MTNR1B risk allele carriers: A randomized, cross-over study.
Topics: Adult; Blood Glucose; Cross-Over Studies; Female; Glucose Tolerance Test; Humans; Meals; Melatonin; | 2018 |
Late dinner impairs glucose tolerance in MTNR1B risk allele carriers: A randomized, cross-over study.
Topics: Adult; Blood Glucose; Cross-Over Studies; Female; Glucose Tolerance Test; Humans; Meals; Melatonin; | 2018 |
Late dinner impairs glucose tolerance in MTNR1B risk allele carriers: A randomized, cross-over study.
Topics: Adult; Blood Glucose; Cross-Over Studies; Female; Glucose Tolerance Test; Humans; Meals; Melatonin; | 2018 |
Melatonin Supplementation Lowers Oxidative Stress and Regulates Adipokines in Obese Patients on a Calorie-Restricted Diet.
Topics: Adipokines; Adult; Caloric Restriction; Female; Humans; Male; Melatonin; Obesity; Oxidative Stress | 2017 |
Dietary supplement of tomato can accelerate urinary aMT6s level and improve sleep quality in obese postmenopausal women.
Topics: Diet; Female; Humans; Male; Melatonin; Middle Aged; Obesity; Postmenopause; Sleep; Solanum lycopersi | 2020 |
A double-blind, placebo-controlled trial related to the effects of melatonin on oxidative stress and inflammatory parameters of obese women.
Topics: Adult; C-Reactive Protein; Double-Blind Method; Female; Humans; Inflammation; Insulin Resistance; In | 2015 |
111 other studies available for melatonin and Obesity
| Article | Year |
|---|---|
Melatonin ameliorates endocrine dysfunction and defective sperm integrity associated with high-fat diet-induced obesity in male Wistar rats.
Topics: Animals; Diet, High-Fat; Male; Melatonin; Obesity; Oxidative Stress; Rats; Rats, Wistar; Spermatozoa | 2022 |
Protective role of melatonin against adipose-hepatic metabolic comorbidities in experimentally induced obese rat model.
Topics: Adipose Tissue; Animals; Diet, High-Fat; Disease Models, Animal; Gene Expression Regulation; Ghrelin | 2021 |
[Melatonin status in obese patients with ovarian dysfunction at reproductive age].
Topics: Adolescent; Adult; Circadian Rhythm; Female; Humans; Melatonin; Obesity; Saliva; Sleep; Young Adult | 2022 |
Melatonin supplementation preserves testicular function by attenuating lactate production and oxidative stress in high fat diet-induced obese rat model.
Topics: Animals; Antioxidants; Diet, High-Fat; Dietary Supplements; Glutathione Peroxidase; Lactic Acid; Mal | 2022 |
Gut Microbiota Dysbiosis Induced by Decreasing Endogenous Melatonin Mediates the Pathogenesis of Alzheimer's Disease and Obesity.
Topics: Alzheimer Disease; Animals; Dysbiosis; Gastrointestinal Microbiome; Inflammation; Melatonin; Mice; O | 2022 |
Agomelatine, a structural analog of melatonin, improves kidney dysfunction through regulating the AMPK/mTOR signaling pathway to promote autophagy in obese rats.
Topics: Acetamides; AMP-Activated Protein Kinases; Animals; Autophagy; Insulin Resistance; Kidney; Male; Mel | 2022 |
Later energy intake relative to mathematically modeled circadian time is associated with higher percentage body fat.
Topics: Adipose Tissue; Circadian Rhythm; Cross-Sectional Studies; Energy Intake; Humans; Melatonin; Obesity | 2023 |
Melatonin treatment improves cognitive deficits by altering inflammatory and neurotrophic factors in the hippocampus of obese mice.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cognition; Cognitive Dysfunction; Diet, High-Fat; Hippoc | 2022 |
Time-restricted eating alters the 24-hour profile of adipose tissue transcriptome in men with obesity.
Topics: Adipose Tissue; Aged; Circadian Rhythm; Fatty Acids, Nonesterified; Humans; Hydrocortisone; Insulins | 2023 |
Therapeutic Target Analysis and Molecular Mechanism of Melatonin - Treated Leptin Resistance Induced Obesity: A Systematic Study of Network Pharmacology.
Topics: Humans; Leptin; Melatonin; Molecular Docking Simulation; Network Pharmacology; Obesity | 2022 |
The melatonergic agonist agomelatine ameliorates high fat diet-induced obesity in mice through the modulation of the gut microbiome.
Topics: Acetamides; Animals; Diet, High-Fat; Dysbiosis; Gastrointestinal Microbiome; Humans; Male; Melatonin | 2022 |
Melatonin protects against body weight gain induced by sleep deprivation in mice.
Topics: Animals; Body Weight; Circadian Rhythm; Melatonin; Mice; Obesity; Sleep; Sleep Deprivation; Weight G | 2022 |
Suppression of obesity by melatonin through increasing energy expenditure and accelerating lipolysis in mice fed a high-fat diet.
Topics: Adipose Tissue, Brown; AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Energy Metabolism; In | 2022 |
Nano-melatonin and-histidine modulate adipokines and neurotransmitters to improve cognition in HFD-fed rats: A formula to study.
Topics: Adipokines; Animals; Brain-Derived Neurotrophic Factor; Cognition; Diet, High-Fat; Histidine; Melato | 2023 |
Evening chronotype is associated with hormonal and metabolic disorders in polycystic ovary syndrome.
Topics: Case-Control Studies; Chronotype; Female; Humans; Insulin; Insulin Resistance; Melatonin; Obesity; P | 2023 |
Evening chronotype is associated with hormonal and metabolic disorders in polycystic ovary syndrome.
Topics: Case-Control Studies; Chronotype; Female; Humans; Insulin; Insulin Resistance; Melatonin; Obesity; P | 2023 |
Evening chronotype is associated with hormonal and metabolic disorders in polycystic ovary syndrome.
Topics: Case-Control Studies; Chronotype; Female; Humans; Insulin; Insulin Resistance; Melatonin; Obesity; P | 2023 |
Evening chronotype is associated with hormonal and metabolic disorders in polycystic ovary syndrome.
Topics: Case-Control Studies; Chronotype; Female; Humans; Insulin; Insulin Resistance; Melatonin; Obesity; P | 2023 |
Evening chronotype is associated with hormonal and metabolic disorders in polycystic ovary syndrome.
Topics: Case-Control Studies; Chronotype; Female; Humans; Insulin; Insulin Resistance; Melatonin; Obesity; P | 2023 |
Evening chronotype is associated with hormonal and metabolic disorders in polycystic ovary syndrome.
Topics: Case-Control Studies; Chronotype; Female; Humans; Insulin; Insulin Resistance; Melatonin; Obesity; P | 2023 |
Evening chronotype is associated with hormonal and metabolic disorders in polycystic ovary syndrome.
Topics: Case-Control Studies; Chronotype; Female; Humans; Insulin; Insulin Resistance; Melatonin; Obesity; P | 2023 |
Evening chronotype is associated with hormonal and metabolic disorders in polycystic ovary syndrome.
Topics: Case-Control Studies; Chronotype; Female; Humans; Insulin; Insulin Resistance; Melatonin; Obesity; P | 2023 |
Evening chronotype is associated with hormonal and metabolic disorders in polycystic ovary syndrome.
Topics: Case-Control Studies; Chronotype; Female; Humans; Insulin; Insulin Resistance; Melatonin; Obesity; P | 2023 |
Adult mice offspring of obese mothers supplemented with melatonin show lessened liver steatosis, inflammation, oxidative stress, and endoplasmic reticulum stress.
Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Dietary Supplements; Endoplasmic Reticulum S | 2023 |
Adult mice offspring of obese mothers supplemented with melatonin show lessened liver steatosis, inflammation, oxidative stress, and endoplasmic reticulum stress.
Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Dietary Supplements; Endoplasmic Reticulum S | 2023 |
Adult mice offspring of obese mothers supplemented with melatonin show lessened liver steatosis, inflammation, oxidative stress, and endoplasmic reticulum stress.
Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Dietary Supplements; Endoplasmic Reticulum S | 2023 |
Adult mice offspring of obese mothers supplemented with melatonin show lessened liver steatosis, inflammation, oxidative stress, and endoplasmic reticulum stress.
Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Dietary Supplements; Endoplasmic Reticulum S | 2023 |
Melatonin increases susceptibility to atrial fibrillation in obesity via Akt signaling impairment in response to lipid overload.
Topics: Animals; Atrial Fibrillation; Insulin Resistance; Lipids; Melatonin; Mice; Mice, Obese; Obesity; Pro | 2023 |
Effect of Melatonin on Redox Enzymes Daily Gene Expression in Perirenal and Subcutaneous Adipose Tissue of a Diet Induced Obesity Model.
Topics: Adipose Tissue; Animals; Diet, High-Fat; Gene Expression; Male; Melatonin; Obesity; Oxidation-Reduct | 2023 |
Leptin, Adiponectin, and Melatonin Modulate Colostrum Lymphocytes in Mothers with Obesity.
Topics: Adiponectin; Calcium; Colostrum; Cross-Sectional Studies; Female; Humans; Infant; Infant, Newborn; L | 2023 |
Intense solar activity reduces urinary 6-sulfatoxymelatonin in patients with COPD.
Topics: Circadian Rhythm; Humans; Melatonin; Obesity; Pulmonary Disease, Chronic Obstructive; Solar Activity | 2023 |
Melatonin modulates the aggravation of pyroptosis, necroptosis, and neuroinflammation following cerebral ischemia and reperfusion injury in obese rats.
Topics: Animals; Brain Ischemia; Inflammation; Male; Melatonin; Necroptosis; Neuroinflammatory Diseases; Obe | 2023 |
Effects of Melatonin Supplementation on Lipid Metabolism and Body Fat Accumulation in Ovariectomized Rats.
Topics: Adipose Tissue; Animals; Body Weight; Dietary Supplements; Fatty Acids; Female; Fibronectins; Humans | 2023 |
Effects of High-Intensity Interval Training on Melatonin Function and Cellular Lymphocyte Apoptosis in Sedentary Middle-Aged Men.
Topics: Aged; Aging; Antioxidants; Apoptosis; Exercise; High-Intensity Interval Training; Humans; Male; Mela | 2023 |
Protective Effects of Melatonin in High-Fat Diet-Induced Hepatic Steatosis via Decreased Intestinal Lipid Absorption and Hepatic Cholesterol Synthesis.
Topics: Animals; Cholesterol; Cytokines; Diet, High-Fat; Lipids; Melatonin; Mice; Non-alcoholic Fatty Liver | 2023 |
Melatonin Supplementation Attenuates the Pro-Inflammatory Adipokines Expression in Visceral Fat from Obese Mice Induced by A High-Fat Diet.
Topics: Adipocytes; Adipokines; Animals; Anti-Inflammatory Agents; Cells, Cultured; Cholesterol; Diet, High- | 2019 |
Melatonin Action on the Activity of Phagocytes from the Colostrum of Obese Women.
Topics: Adult; Body Mass Index; Breast Feeding; Colostrum; Female; Humans; Melatonin; Obesity; Phagocytes; P | 2019 |
Effects of theabrownin on serum metabolites and gut microbiome in rats with a high-sugar diet.
Topics: Animals; Bacteria; Body Weight; Catechin; Cecum; Cholic Acid; Dietary Sugars; Gastrointestinal Micro | 2019 |
Is melatonin, leptin or their combination more effective on oxidative stress and folliculogenesis in the obese rats?
Topics: Adipose Tissue; Animals; Apoptosis; Drug Therapy, Combination; Female; Leptin; Melatonin; Obesity; O | 2020 |
Mitochondrial Oxidative Phosphorylation Function and Mitophagy in Ischaemic/Reperfused Hearts from Control and High-Fat Diet Rats: Effects of Long-Term Melatonin Treatment.
Topics: Animals; Antioxidants; Diet, High-Fat; Dietary Sucrose; Disease Models, Animal; Male; Melatonin; Mit | 2020 |
Effects of Melatonin on Lipid Metabolism and Circulating Irisin in Sprague-Dawley Rats with Diet-Induced Obesity.
Topics: Adipose Tissue, Brown; Adipose Tissue, White; Animals; Anti-Obesity Agents; Cholesterol; Fibronectin | 2020 |
Effect of diurnal intermittent fasting during Ramadan on ghrelin, leptin, melatonin, and cortisol levels among overweight and obese subjects: A prospective observational study.
Topics: Adult; Circadian Rhythm; Diet; Energy Intake; Fasting; Female; Ghrelin; Hemodynamics; Humans; Hydroc | 2020 |
Melatonin reverses the loss of the anticontractile effect of perivascular adipose tissue in obese rats.
Topics: Adipose Tissue; Animals; Aorta; Male; Melatonin; Obesity; Oxidative Stress; Rats; Rats, Wistar; Reac | 2021 |
Obese
Topics: Animals; ARNTL Transcription Factors; Circadian Rhythm; CLOCK Proteins; Female; Hypothalamus; Male; | 2021 |
Metabolomic Profiles of Shift Workers and Day Workers: A Cross-Sectional Study.
Topics: Adult; Case-Control Studies; Cholesterol; Cholesterol, LDL; Circadian Rhythm; Cross-Sectional Studie | 2021 |
In vitro gastrointestinal digestion and simulated colonic fermentation of pistachio nuts determine the bioaccessibility and biosynthesis of chronobiotics.
Topics: Animals; Antioxidants; Biological Availability; Chronobiology Phenomena; Colon; Dietary Fiber; Diges | 2021 |
Circadian disruption-induced metabolic syndrome in mice is ameliorated by oat β-glucan mediated by gut microbiota.
Topics: Animals; Avena; beta-Glucans; Cichorium intybus; Circadian Rhythm; Gastrointestinal Microbiome; Inul | 2021 |
Melatonin Improves Mitochondrial Respiration in Syncytiotrophoblasts From Placentas of Obese Women.
Topics: Adult; Antioxidants; Body Mass Index; Energy Metabolism; Female; Humans; Melatonin; Mitochondria; Ob | 2018 |
Possible effects of some agents on the injured nerve in obese rats: A stereological and electron microscopic study.
Topics: Acetylcarnitine; Animals; Female; Leptin; Melatonin; Microscopy, Electron; Nerve Regeneration; Obesi | 2017 |
High-fat diet-induced plasma protein and liver changes in obese rats can be attenuated by melatonin supplementation.
Topics: alpha 1-Antitrypsin; Animals; Biomarkers; Blood Glucose; Blood Proteins; Body Weight; Complement C4; | 2017 |
Melatonin protects against maternal obesity-associated oxidative stress and meiotic defects in oocytes via the SIRT3-SOD2-dependent pathway.
Topics: Acetylation; Animals; Antioxidants; Diet, High-Fat; Drug Evaluation, Preclinical; Embryonic Developm | 2017 |
Later circadian timing of food intake is associated with increased body fat.
Topics: Adiposity; Adolescent; Adult; Body Composition; Body Mass Index; Circadian Rhythm; Cohort Studies; C | 2017 |
Melatonin Prevents the Harmful Effects of Obesity on the Brain, Including at the Behavioral Level.
Topics: Animals; Autophagy; Behavior, Animal; Biomarkers; Body Weight; Brain; Cytokines; Endoplasmic Reticul | 2018 |
[METABOLIC SECRETION IN REPRODUCTIVE AGE WOMEN WITH OBESITY].
Topics: Adult; Case-Control Studies; Dyslipidemias; Female; Humans; Insulin Resistance; Lipid Metabolism; Me | 2017 |
Melatonin increases brown adipose tissue mass and function in Zücker diabetic fatty rats: implications for obesity control.
Topics: Adipose Tissue, Brown; Animals; Male; Melatonin; Obesity; Rats; Rats, Zucker | 2018 |
Melatonin expression in periodontitis and obesity: An experimental in-vivo investigation.
Topics: Alveolar Bone Loss; Animals; Dental Health Surveys; Immunoassay; Male; Melatonin; Obesity; Periodont | 2018 |
Melatonin treatment suppresses appetite genes and improves adipose tissue plasticity in diet-induced obese zebrafish.
Topics: Adipocytes; Adipose Tissue; Animals; Appetite; Body Mass Index; Brain Chemistry; Cell Count; Cell Si | 2018 |
Melatonin improves cardiac function in a mouse model of heart failure with preserved ejection fraction.
Topics: Adipokines; Animals; Antioxidants; Apoptosis; Diet, High-Fat; Disease Models, Animal; Heart Failure; | 2018 |
Melatonin as adjunctive therapy in the treatment of periodontitis associated with obesity.
Topics: Animals; Chlorhexidine; Melatonin; Obesity; Periodontitis; Rats; Rats, Wistar | 2018 |
Obesity-associated alterations in cardiac connexin-43 and PKC signaling are attenuated by melatonin and omega-3 fatty acids in female rats.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Connexin 43; Dietary Sucrose; Fatty Acids, Om | 2019 |
Too Late and Not Enough: School Year Sleep Duration, Timing, and Circadian Misalignment Are Associated with Reduced Insulin Sensitivity in Adolescents with Overweight/Obesity.
Topics: Actigraphy; Adolescent; Body Mass Index; Circadian Rhythm; Female; Follow-Up Studies; Humans; Insuli | 2019 |
Morning Circadian Misalignment Is Associated With Insulin Resistance in Girls With Obesity and Polycystic Ovarian Syndrome.
Topics: Actigraphy; Adolescent; Circadian Rhythm; Cross-Sectional Studies; Fasting; Female; Humans; Insulin | 2019 |
Morning Circadian Misalignment Is Associated With Insulin Resistance in Girls With Obesity and Polycystic Ovarian Syndrome.
Topics: Actigraphy; Adolescent; Circadian Rhythm; Cross-Sectional Studies; Fasting; Female; Humans; Insulin | 2019 |
Morning Circadian Misalignment Is Associated With Insulin Resistance in Girls With Obesity and Polycystic Ovarian Syndrome.
Topics: Actigraphy; Adolescent; Circadian Rhythm; Cross-Sectional Studies; Fasting; Female; Humans; Insulin | 2019 |
Morning Circadian Misalignment Is Associated With Insulin Resistance in Girls With Obesity and Polycystic Ovarian Syndrome.
Topics: Actigraphy; Adolescent; Circadian Rhythm; Cross-Sectional Studies; Fasting; Female; Humans; Insulin | 2019 |
Melatonin appears to protect against steroidogenic collapse in both mice fed with high-fat diet and H
Topics: Animals; Cell Line; Cholesterol Side-Chain Cleavage Enzyme; Diet, High-Fat; Disease Models, Animal; | 2019 |
The effects of high-fructose corn syrup consumption on testis physiopathology-The ameliorative role of melatonin.
Topics: Animals; Antioxidants; Catalase; Disease Models, Animal; High Fructose Corn Syrup; Humans; Infertili | 2019 |
Melatonin improves insulin sensitivity independently of weight loss in old obese rats.
Topics: Aging; Animals; Antioxidants; Dietary Supplements; Drug Evaluation, Preclinical; Glucose Metabolism | 2013 |
Obesity-related dysfunction of the aorta and prevention by melatonin treatment in ob/ob mice.
Topics: Animals; Aorta; Male; Melatonin; Mice; Mice, Obese; Obesity | 2013 |
Chronobiology: stepping out of time.
Topics: Animals; Benzofurans; Circadian Rhythm; CLOCK Proteins; Cyclopropanes; Efficiency; Humans; Melatonin | 2013 |
Melatonin and omentin: influence factors in the obstructive sleep apnoea syndrome?
Topics: Biomarkers; Body Mass Index; Circadian Rhythm; Continuous Positive Airway Pressure; Cytokines; Down- | 2013 |
Resveratrol- and melatonin-abated ovariectomy and fructose diet-induced obesity and metabolic alterations in female rats.
Topics: Administration, Oral; Animals; Antioxidants; Diabetes Mellitus; Diet; Disease Models, Animal; Female | 2014 |
Anticontractile activity of perivascular fat in obese mice and the effect of long-term treatment with melatonin.
Topics: Adiponectin; Adipose Tissue; Animals; Antioxidants; Body Weight; Hypoxia; Inflammation; Male; Melato | 2014 |
NADPH oxidase inhibitor, apocynin, improves renal glutathione status in Zucker diabetic fatty rats: a comparison with melatonin.
Topics: Acetophenones; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Enzyme Inhibito | 2014 |
The relationship between obesity and exposure to light at night: cross-sectional analyses of over 100,000 women in the Breakthrough Generations Study.
Topics: Adult; Body Mass Index; Circadian Rhythm; Cross-Sectional Studies; Female; Humans; Light; Logistic M | 2014 |
Toward a chronobiological characterization of obesity and metabolic syndrome in clinical practice.
Topics: Adiponectin; Adult; Biomarkers; Blood Glucose; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; | 2015 |
Short-term melatonin consumption protects the heart of obese rats independent of body weight change and visceral adiposity.
Topics: Animals; Body Weight; Heart; Intra-Abdominal Fat; Melatonin; Obesity; Rats | 2014 |
Mitochondrial and metabolic dysfunction in renal convoluted tubules of obese mice: protective role of melatonin.
Topics: Animals; Apoptosis; GTP Phosphohydrolases; Kidney Tubules; Male; Melatonin; Mice; Mitochondria; Obes | 2014 |
Effect of melatonin on cellular composition of the spleen and parameters of lipid metabolism in rats with alimentary obesity.
Topics: Animals; Cholesterol; Diet, High-Fat; Drug Evaluation, Preclinical; Female; Immunologic Factors; Leu | 2014 |
Impact of circadian misalignment on energy metabolism during simulated nightshift work.
Topics: Adult; Analysis of Variance; Circadian Rhythm; Eating; Electromyography; Energy Metabolism; Female; | 2014 |
Impact of circadian misalignment on energy metabolism during simulated nightshift work.
Topics: Adult; Analysis of Variance; Circadian Rhythm; Eating; Electromyography; Energy Metabolism; Female; | 2014 |
Impact of circadian misalignment on energy metabolism during simulated nightshift work.
Topics: Adult; Analysis of Variance; Circadian Rhythm; Eating; Electromyography; Energy Metabolism; Female; | 2014 |
Impact of circadian misalignment on energy metabolism during simulated nightshift work.
Topics: Adult; Analysis of Variance; Circadian Rhythm; Eating; Electromyography; Energy Metabolism; Female; | 2014 |
Melatonin reduces hepatic mitochondrial dysfunction in diabetic obese rats.
Topics: Animals; Blotting, Western; Cell Line, Tumor; Diabetes Mellitus, Experimental; Humans; Immunohistoch | 2015 |
Melatonin increases intracellular calcium in the liver, muscle, white adipose tissues and pancreas of diabetic obese rats.
Topics: Adipose Tissue, White; Animals; Calcium; Diabetes Mellitus, Type 2; Humans; Insulin; Liver; Male; Me | 2015 |
Melatonin reduces obesity and restores adipokine patterns and metabolism in obese (ob/ob) mice.
Topics: Adipokines; Adipose Tissue; Animals; Diet; Dietary Supplements; Fluorescent Antibody Technique; Infl | 2015 |
Hepatic Macrosteatosis Is Partially Converted to Microsteatosis by Melatonin Supplementation in ob/ob Mice Non-Alcoholic Fatty Liver Disease.
Topics: Animals; Antioxidants; beta Catenin; Calnexin; Disease Models, Animal; Disease Progression; Endoplas | 2016 |
Administration of Melatonin and Metformin Prevents Deleterious Effects of Circadian Disruption and Obesity in Male Rats.
Topics: Adiposity; Animals; Central Nervous System Depressants; Circadian Rhythm; Glucose Intolerance; Hypog | 2016 |
The association of pineal gland volume and body mass in obese and normal weight individuals: a pilot study.
Topics: Animals; Body Mass Index; Circadian Rhythm; Energy Metabolism; Female; Homeostasis; Humans; Image In | 2016 |
Effects of Melatonin, Aluminum Oxide, and Polymethylsiloxane Complex on the Expression of LYVE-1 in the Liver of Mice with Obesity and Type 2 Diabetes Mellitus.
Topics: Aluminum Oxide; Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Ani | 2016 |
Melatonin prevents obesity through modulation of gut microbiota in mice.
Topics: Animals; Bacteroidetes; Blotting, Western; Central Nervous System Depressants; Diet, High-Fat; Fatty | 2017 |
Strategies to control antipsychotic-induced weight gain.
Topics: Anti-Obesity Agents; Antipsychotic Agents; Awareness; Body Weight; Bupropion; Clinical Competence; F | 2008 |
NEU-P11, a novel melatonin agonist, inhibits weight gain and improves insulin sensitivity in high-fat/high-sucrose-fed rats.
Topics: Animals; Body Mass Index; Body Weight; Dietary Fats; Dietary Sucrose; Eating; Glucose; Insulin; Male | 2009 |
Melatonin effect on plasma adiponectin, leptin, insulin, glucose, triglycerides and cholesterol in normal and high fat-fed rats.
Topics: Adipokines; Analysis of Variance; Animals; Blood Glucose; Body Weight; Cholesterol; Dietary Fats; In | 2010 |
Chronic melatonin consumption prevents obesity-related metabolic abnormalities and protects the heart against myocardial ischemia and reperfusion injury in a prediabetic model of diet-induced obesity.
Topics: Animals; Antioxidants; Male; Melatonin; Myocardial Reperfusion Injury; Obesity; Prediabetic State; R | 2011 |
Beneficial effects of melatonin on obesity and lipid profile in young Zucker diabetic fatty rats.
Topics: Animals; Antioxidants; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mel | 2011 |
Recognition and assessment of shift work disorder.
Topics: Animals; Biological Clocks; Circadian Rhythm; Diabetes Mellitus, Type 2; Energy Metabolism; Hormones | 2011 |
Potential of melatonin for the treatment or prevention of obesity: an urgent need to include weight reduction as a secondary outcome in clinical trials of melatonin in obese patients with sleep disorders.
Topics: Central Nervous System Depressants; Clinical Trials as Topic; Humans; Melatonin; Obesity; Sleep Wake | 2012 |
Daily rhythms of plasma melatonin, but not plasma leptin or leptin mRNA, vary between lean, obese and type 2 diabetic men.
Topics: Analysis of Variance; Circadian Rhythm; Diabetes Mellitus, Type 2; DNA Primers; Gene Expression Prof | 2012 |
Seasonal differences in melatonin concentrations and heart rates during sleep in obese subjects in Japan.
Topics: Adult; Circadian Rhythm; Female; Heart Rate; Humans; Japan; Male; Melatonin; Obesity; Seasons; Sleep | 2013 |
Exposure to light at night, nocturnal urinary melatonin excretion, and obesity/dyslipidemia in the elderly: a cross-sectional analysis of the HEIJO-KYO study.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Circadian Rhythm; Cross-Sectional Studies; Dyslipidem | 2013 |
Antioxidant activity of melatonin in diabetes in relation to the regulation and levels of plasma Cu, Zn, Fe, Mn, and Se in Zucker diabetic fatty rats.
Topics: Animals; Antioxidants; Copper; Diabetes Mellitus, Experimental; Dietary Supplements; Iron; Male; Man | 2013 |
Melatonin secretion and increased daytime sleepiness in childhood craniopharyngioma patients.
Topics: Adolescent; Adult; Astrocytoma; Child; Child, Preschool; Craniopharyngioma; Female; Humans; Hydrocor | 2002 |
Melatonin reduces body weight gain in Sprague Dawley rats with diet-induced obesity.
Topics: Adipose Tissue; Animals; Blood Glucose; Dietary Fats; Eating; Insulin; Leptin; Male; Melatonin; Obes | 2003 |
Circadian neuroendocrine functions in disorders of eating behavior.
Topics: Adult; Anorexia Nervosa; Chronobiology Disorders; Energy Intake; Female; Growth Hormone; Humans; Hyd | 1997 |
Does obesity induce resistance to the long-term cardiovascular and metabolic actions of melanocortin 3/4 receptor activation?
Topics: Animals; Blood Pressure; Diet; Energy Intake; Injections, Intraventricular; Insulin; Insulin Resista | 2006 |
Gender-related differences in urinary 6-sulfatoxymelatonin levels in obese pubertal individuals.
Topics: Adolescent; Child; Child, Preschool; Circadian Rhythm; Female; Humans; Male; Melatonin; Obesity; Pub | 2006 |
Melatonin treatment in obese patients with childhood craniopharyngioma and increased daytime sleepiness.
Topics: Adolescent; Adult; Astrocytoma; Child; Child, Preschool; Circadian Rhythm; Craniopharyngioma; Disord | 2006 |
Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.
Topics: Abdominal Fat; Animals; Antipsychotic Agents; Benzodiazepines; Energy Metabolism; Female; Lipid Meta | 2007 |
Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.
Topics: Abdominal Fat; Animals; Antipsychotic Agents; Benzodiazepines; Energy Metabolism; Female; Lipid Meta | 2007 |
Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.
Topics: Abdominal Fat; Animals; Antipsychotic Agents; Benzodiazepines; Energy Metabolism; Female; Lipid Meta | 2007 |
Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.
Topics: Abdominal Fat; Animals; Antipsychotic Agents; Benzodiazepines; Energy Metabolism; Female; Lipid Meta | 2007 |
Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.
Topics: Abdominal Fat; Animals; Antipsychotic Agents; Benzodiazepines; Energy Metabolism; Female; Lipid Meta | 2007 |
Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.
Topics: Abdominal Fat; Animals; Antipsychotic Agents; Benzodiazepines; Energy Metabolism; Female; Lipid Meta | 2007 |
Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.
Topics: Abdominal Fat; Animals; Antipsychotic Agents; Benzodiazepines; Energy Metabolism; Female; Lipid Meta | 2007 |
Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.
Topics: Abdominal Fat; Animals; Antipsychotic Agents; Benzodiazepines; Energy Metabolism; Female; Lipid Meta | 2007 |
Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.
Topics: Abdominal Fat; Animals; Antipsychotic Agents; Benzodiazepines; Energy Metabolism; Female; Lipid Meta | 2007 |
Intake of melatonin is associated with amelioration of physiological changes, both metabolic and morphological pathologies associated with obesity: an animal model.
Topics: Animals; Arteries; Blood Pressure; Body Weight; Cholesterol; Dietary Fats; Electric Stimulation; Ele | 2007 |
Melatonin and estradiol effects on food intake, body weight, and leptin in ovariectomized rats.
Topics: Analysis of Variance; Animals; Body Weight; Cholesterol; Disease Models, Animal; Eating; Estradiol C | 2007 |
Night shift work and the risk of endometrial cancer.
Topics: Adult; Body Mass Index; Cohort Studies; Endometrial Neoplasms; Female; Humans; Melatonin; Middle Age | 2007 |
Seasonal obesity in Syrian hamsters: effects of age, diet, photoperiod, and melatonin.
Topics: Age Factors; Animals; Body Weight; Cricetinae; Diet; Dietary Fats; Female; Melatonin; Mesocricetus; | 1984 |
The daily profile of plasma melatonin in obese and Prader-Willi syndrome children.
Topics: Child; Chromatography, High Pressure Liquid; Circadian Rhythm; Female; Humans; Male; Melatonin; Obes | 1982 |
Can "resetting" hormonal rhythms treat illness?
Topics: Animals; Bromocriptine; Circadian Rhythm; Clinical Trials, Phase III as Topic; Darkness; Diabetes Me | 1995 |
Effects of both a melatonin agonist and antagonist on seasonal changes in body mass and energy intake in the garden dormouse.
Topics: Animals; Body Weight; Circadian Rhythm; Energy Intake; Energy Metabolism; Male; Melatonin; Motor Act | 1996 |
Obesity treated with phototherapy: four case studies.
Topics: Dietary Carbohydrates; Female; Food Preferences; Humans; Melatonin; Middle Aged; Obesity; Photothera | 1996 |
Behavioral and neuroendocrine characteristics of the night-eating syndrome.
Topics: Adult; Anorexia; Circadian Rhythm; Feeding and Eating Disorders; Feeding Behavior; Female; Humans; H | 1999 |
Endocrinological disorders. Focusing on melatonin's interactions.
Topics: Adolescent; Adult; Body Mass Index; Circadian Rhythm; Endocrine System Diseases; Female; Humans; Hyp | 1999 |
Melatonin in postmenopausal females.
Topics: Depression; Female; Humans; Hyperprolactinemia; Melatonin; Middle Aged; Obesity; Postmenopause; Refe | 2000 |
Assessment of the relationship between circadian variations of salivary melatonin levels and type I collagen metabolism in postmenopausal obese women.
Topics: Body Constitution; Body Mass Index; Bone and Bones; Circadian Rhythm; Collagen; Collagen Type I; Fem | 2001 |
Effect of short-term fasting on nocturnal melatonin secretion in obesity.
Topics: Administration, Oral; Adult; Blood Glucose; Body Mass Index; Body Weight; Circadian Rhythm; Fasting; | 1992 |
Nocturnal melatonin secretion in thyroid disease and in obesity.
Topics: Adult; Circadian Rhythm; Female; Humans; Hypothyroidism; Male; Melatonin; Middle Aged; Obesity; Pine | 1991 |
Hormonal circadian rhythms in eating disorders.
Topics: Adult; Anorexia Nervosa; Body Temperature Regulation; Circadian Rhythm; Female; Growth Hormone; Horm | 1990 |
Melatonin and pituitary-gonadal function in disorders of eating behavior.
Topics: Adolescent; Adult; Anorexia Nervosa; Body Temperature; Circadian Rhythm; Female; Gonadotropin-Releas | 1989 |
Circadian fluctuation of plasma melatonin in Prader-Willi's syndrome and obesity.
Topics: Adolescent; Adult; Child; Circadian Rhythm; Estradiol; Female; Follicle Stimulating Hormone; Growth | 1986 |
Nocturnal urinary melatonin excretion and plasma cortisol levels in children and adolescents after a single oral dose of dexamethasone.
Topics: Adolescent; Child; Dexamethasone; Female; Humans; Hydrocortisone; Male; Melatonin; Obesity; Pituitar | 1986 |
Melatonin inhibition of insulin secretion in the rat and mouse.
Topics: Animals; Blood Glucose; Depression, Chemical; Glucose; Glucose Tolerance Test; Hyperglycemia; Insuli | 1974 |